var title_f22_24_22912="Eval Rx oropharyngeal dysphagia";
var content_f22_24_22912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Evaluation and management of oropharyngeal dysphagia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 420px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Summary of the clinical approach and key objectives in the management of oropharyngeal dysphagia.",
"    </strong>",
"    The objective is to reach a box targeted by a red arrow, which equates to a specific management strategy. Blue-headed arrows indicate a suggested pathway to proceed with the evaluation.",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; Rx: therapy; CVA: cerebrovascular accident.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Cook, IJ, Kahrilas, PJ. AGA: Technical review: Management of oropharyngeal dysphagia. Gastroenterology 1999; 116:455.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22912=[""].join("\n");
var outline_f22_24_22912=null;
var title_f22_24_22913="Scapular assistance maneuver";
var content_f22_24_22913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/83146/Scapul_assist_maneuv_video.mp4?title=Scapular+assistance+maneuver\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Scapular assistance maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scapular assistance maneuver helps to identify dysfunction of the muscles that stabilize the scapula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22913=[""].join("\n");
var outline_f22_24_22913=null;
var title_f22_24_22914="Exencephaly";
var content_f22_24_22914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exencephalic fetus at 17 postmenstrual weeks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The facial bones can be observed. However, above the level of the forehead no distinct cranial vault is seen. The brain falls to one side and its appearance is that of a homogeneous and solid appearing structure (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22914=[""].join("\n");
var outline_f22_24_22914=null;
var title_f22_24_22915="Flunisolide (nasal): Pediatric drug information";
var content_f22_24_22915=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flunisolide (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30691?source=see_link\">",
"    see \"Flunisolide (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=see_link\">",
"    see \"Flunisolide (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8097134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flunisolide&reg;;",
"     </li>",
"     <li>",
"      Nasalide&reg;;",
"     </li>",
"     <li>",
"      Rhinalar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10482306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Intranasal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10482364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30691?source=see_link\">",
"      see \"Flunisolide (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal:",
"     <b>",
"      Seasonal and perennial rhinitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents 6-14 years: Initial: 1 spray to each nostril 3 times/day or 2 sprays to each nostril 2 times/day; maximum dose: 4 sprays to each nostril per day; after symptoms are controlled, dose should be reduced to lowest effective amount; maintenance: 1 spray each nostril once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;15 years and Adults: Initial: 2 sprays to each nostril twice daily; may increase in 4-7 days if needed to 2 sprays to each nostril 3 times/day; maximum dose: 8 sprays to each nostril per day; after symptoms are controlled, dose should be reduced to lowest effective amount; maintenance: 1 spray to each nostril once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8097304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]: 25 mcg/actuation (25 mL); 29 mcg/actuation (25 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8097135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10482365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well before use; do not spray in eyes. Clear nasal passages by blowing nose prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10482335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10482307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of seasonal or perennial rhinitis (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8097076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flunisolide may be confused with Flumadine&reg;, fluocinonide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8097218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal burning/stinging, nasal congestion, nasal dryness, nasal irritation, rhinitis, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Loss of smell",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10482324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flunisolide or any component; untreated nasal mucosa infection",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10482326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended dosages; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercorticism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth). Use flunisolide with extreme caution in patients with respiratory tuberculosis; untreated bacterial, fungal, systemic viral or parasitic infections; or ocular herpes simplex. Localized",
"     <i>",
"      Candida",
"     </i>",
"     infections of the nose and pharynx have been reported rarely; interruption of therapy may be necessary while antifungal therapy is employed. Corticosteroids impair wound healing; avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma; allow healing to occur before use. Use of nasal flunisolide in place of systemic corticosteroids may unmask allergies (eg, eczema, rhinitis) that were previously controlled by the systemic corticosteroids. Rare cases of immediate hypersensitivity reactions, nasal septum perforation, increased IOP, glaucoma, or cataracts may occur with intranasal corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13365170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HPA suppression or hypercorticism (Cushing's syndrome) may occur with use of higher than recommended doses or at typical doses in susceptible patients. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use, with stress, or when converting from systemic to topical corticosteroid therapy; withdrawal or discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8097223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8097162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8097163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of allergic rhinitis during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10482384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check mucus membranes for signs of fungal infection; monitor growth in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10482336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10482337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical effects are due to a direct local effect rather than systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within a few days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect:1-2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10482343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 50%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10482385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=see_link\">",
"      see \"Flunisolide (nasal): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Full response to this medication may not be seen for 2-5 weeks. Use regularly. Do not stop treatment, even if feeling better. Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval. Avoid exposure to chickenpox or measles; if exposed, seek medical advice without delay. Report sore mouth or mouth lesions, persistent headache, or nosebleeds to physician; carefully read and follow the patient instructions for use leaflet that accompanies the product.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15984 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22915=[""].join("\n");
var outline_f22_24_22915=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097134\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482306\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482364\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097304\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097135\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482365\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482335\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482307\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097218\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482324\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482326\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365170\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299346\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097162\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097163\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482384\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482336\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482337\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482343\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482385\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30691?source=related_link\">",
"      Flunisolide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=related_link\">",
"      Flunisolide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/34/9766?source=related_link\">",
"      Flunisolide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/49/34581?source=related_link\">",
"      Flunisolide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_24_22916="Pramoxine and hydrocortisone: Patient drug information";
var content_f22_24_22916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pramoxine and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/61/39892?source=see_link\">",
"     see \"Pramoxine and hydrocortisone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Analpram E&trade;;",
"     </li>",
"     <li>",
"      Analpram HC&reg;;",
"     </li>",
"     <li>",
"      Epifoam&reg;;",
"     </li>",
"     <li>",
"      Pramosone E&trade;;",
"     </li>",
"     <li>",
"      Pramosone&reg;;",
"     </li>",
"     <li>",
"      ProCort&reg;;",
"     </li>",
"     <li>",
"      ProctoFoam&reg; HC;",
"     </li>",
"     <li>",
"      Zypram&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pramox&reg; HC;",
"     </li>",
"     <li>",
"      Proctofoam&trade;-HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat signs of hemorrhoids or rectal irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702778",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pramoxine, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding from rectum or rectal pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696165",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use an applicator to put in rectal foam.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3567602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put the applicator into your rectum.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3567622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place foam on clean area and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Foam:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store upright at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11836 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22916=[""].join("\n");
var outline_f22_24_22916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212420\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212421\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015109\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015108\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015113\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015114\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015116\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015111\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015112\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015117\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015118\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/61/39892?source=related_link\">",
"      Pramoxine and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_24_22917="Paclitaxel (nanoparticle albumin bound): Patient drug information";
var content_f22_24_22917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Paclitaxel (nanoparticle albumin bound): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/29/8664?source=see_link\">",
"     see \"Paclitaxel (nanoparticle albumin bound): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Abraxane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11571444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abraxane&reg; for Injectable Suspension",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is more than 1 brand of this drug. One brand cannot safely be used for the other. Your doctor will tell you about any needed change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4090502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may irritate the vein. It may burn the skin if the drug leaks from the vein when it is given. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to paclitaxel or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701370",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3532549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699037",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11396 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22917=[""].join("\n");
var outline_f22_24_22917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205672\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11571444\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028146\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028148\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028147\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028152\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028153\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028155\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028150\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028157\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/29/8664?source=related_link\">",
"      Paclitaxel (nanoparticle albumin bound): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_24_22918="Coronary stabilizer";
var content_f22_24_22918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronary stabilizer and its carrying wound spreader",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The coronary stabilizer prevents movement of the artery during the surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22918=[""].join("\n");
var outline_f22_24_22918=null;
var title_f22_24_22919="Sequestration CXR III";
var content_f22_24_22919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76571%7EPULM%2F74913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76571%7EPULM%2F74913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration right lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a mass at the right base, which obscures the right hemidiaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration right lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a right basilar multicystic mass with systemic arterial supply.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22919=[""].join("\n");
var outline_f22_24_22919=null;
var title_f22_24_22920="Methamphetamine abuse and dependence: Epidemiology, clinical manifestations, course, assessment, and diagnosis";
var content_f22_24_22920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Methamphetamine abuse and dependence: Epidemiology, clinical manifestations, course, assessment, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22920/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22920/contributors\">",
"     Martin Paulus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22920/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22920/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22920/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22920/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/24/22920/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H93519170\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine is a psychostimulant that causes the release and blocks the reuptake of monoamine neurotransmitters, including dopamine, norepinephrine, and serotonin. Methamphetamine is most often smoked or snorted and is less commonly injected or ingested orally.",
"   </p>",
"   <p>",
"    Clinical manifestations of methamphetamine use include increased energy and alertness, euphoria, sympathetic nervous system activation, decreased need for sleep, weight loss, dry mouth leading to tooth decay, and chronic adverse mood and cognitive changes, including irritability, anxiety, aggression, panic, suspiciousness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paranoia, hallucinations, executive dysfunction, and memory impairment.",
"   </p>",
"   <p>",
"    This topic describes the epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis of methamphetamine abuse and dependence. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of other stimulant abuse and dependence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93519177\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine use varies geographically, but overall, amphetamine-type stimulants, which include methamphetamine, are the fastest rising drug of abuse worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Amphetamine-type stimulants have become the second most widely used class of illicit drugs worldwide, with use increasing in Asia and Oceania [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An estimated 4.7 million Americans (2.1 percent of the United States [US] population) have been reported to have tried methamphetamine at some time in their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/4\">",
"     4",
"    </a>",
"    ]. The rate of methamphetamine use in the US has been found to be similar among men and women (0.32 versus 0.23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methamphetamine use in the US increased in the 1990s, reaching epidemic proportions in the early 2000s in the western and midwestern parts of the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/6\">",
"     6",
"    </a>",
"    ]. As a consequence of regulations reducing access to methamphetamine precursors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    ), US prevalence indicators for the drug began to decrease in the mid-2000s [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2010 US National Survey on Drug Use and Health (NSDUH) found the rate of use among Americans, age 12 years and older, decreased between 2006 and 2010, from 0.3 percent to 0.1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The number of individuals 12 and older who started using methamphetamine decreased from 299,000 in 2002 to 105,000 in 2010 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, other sources of data, such as law enforcement groups, welfare agencies and substance use treatment programs, indicate that methamphetamine continues to be a significant public health problem [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of methamphetamine use in other countries were found to be similar to US rates in a 2012 United Nations report, ranging from 0.2 to 1.3 percent of the population aged 15 to 64 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15336338\">",
"    <span class=\"h2\">",
"     Comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with methamphetamine dependence have shown high rates of comorbid psychiatric disorders in small studies. As an example, in a study of 189 patients with methamphetamine dependence the following co-occurring psychiatric disorders were found [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary psychotic disorder, 28.6 percent, including schizophrenia, schizoaffective disorder, or a manic episode",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary mood disorder, 32.3 percent, including bipolar disorder and major depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary anxiety disorder, 26.5 percent, including generalized anxiety disorder, social phobia, and posttraumatic stress disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Approximately one-third to 40 percent of individuals with methamphetamine use disorder in samples studied has been assigned a lifetime diagnosis of ADHD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depressive symptoms commonly co-occur with methamphetamine use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/12\">",
"     12",
"    </a>",
"    ]. In a sample of 214 individuals who used methamphetamine at least weekly and were enrolled in a clinical trial of a psychotherapeutic treatment for methamphetamine abuse, more than 70 percent had depressive symptoms of a severity meeting diagnostic criteria for major depression. Greater depressive symptom severity in the sample was associated with greater methamphetamine use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15336352\">",
"    <span class=\"h2\">",
"     Health consequences",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24480181\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine use has been associated with increased risk of early mortality. As an example, in a retrospective study of 1254 subjects with methamphetamine dependence who were admitted to a psychiatric center, the five-year rate of all-cause mortality was approximately 5 percent, an observed death rate 26 times greater than expected in women and six times greater than expected in men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24480095\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of clinical and experimental evidence concluded that individuals who use methamphetamine are at an increased risk of heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/15\">",
"     15",
"    </a>",
"    ]. The review further concluded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of heart disease is not likely to be limited to the duration of the individual&rsquo;s methamphetamine use",
"     </li>",
"     <li>",
"      The risk is greater among chronic methamphetamine users",
"     </li>",
"     <li>",
"      Pre-existing cardiac pathology increases the risk of an acute cardiac event",
"     </li>",
"     <li>",
"      Methamphetamine use is likely to exacerbate the risk posed by cardiac pathology from other causes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link\">",
"       \"Overview of the possible risk factors for cardiovascular disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24480195\">",
"    <span class=\"h3\">",
"     Risky sexual behaviors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Users of methamphetamine typically have more sexual partners and are more likely to engage in risky sexual behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/16-18\">",
"     16-18",
"    </a>",
"    ], partly because methamphetamine enhances libido. As an example, in the 2003 National Youth Risk Behavior Survey of a nationally representative sample of 9",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade high school students in the US, lifetime methamphetamine use was associated with greater likelihoods of recent sexual intercourse, multiple recent sexual partners, and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-risk sexual behaviors and drug injection have been proposed as possible causal factors in HIV transmission, which may be elevated among individuals using methamphetamine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93519191\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine is a psychostimulant that causes an increase in the synapse of monoamine neurotransmitters including dopamine, norepinephrine, and serotonin via the following molecular mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Redistribution of catecholamines from synaptic vesicles to the cytosol",
"     </li>",
"     <li>",
"      Reversal of transport of neurotransmitter through plasma membrane transporters",
"     </li>",
"     <li>",
"      Blocking the activity of monoamine transporters",
"     </li>",
"     <li>",
"      Decreasing the expression of dopamine transporters at the cell surface",
"     </li>",
"     <li>",
"      Inhibiting monoamine oxidase activity",
"     </li>",
"     <li>",
"      Increasing the activity and expression of tyrosine hydroxylase, the critical enzyme for synthesizing dopamine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methamphetamine use exerts it effects via the dopamine system. The consequence of the above processes is that dopamine becomes highly concentrated in the synaptic cleft and is available to post-synaptic uptake and subsequent signaling. A figure depicts the chemical structure of methamphetamine (",
"    <a class=\"graphic graphic_figure graphicRef81294 \" href=\"UTD.htm?28/46/29420\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Neuroimaging studies have shown that methamphetamine dependent individuals have",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower striatal and orbitofrontal dopamine",
"      <span class=\"nowrap\">",
"       D",
"       <sub>",
"        2",
"       </sub>",
"       /D",
"       <sub>",
"        3",
"       </sub>",
"      </span>",
"      receptor availability [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/20,21\">",
"       20,21",
"      </a>",
"      ], which is associated with higher impulsivity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lower dopamine transporter and vesicular monoamine transporter type-2 in the striatum [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/23\">",
"       23",
"      </a>",
"      ] as well as in orbitofrontal and dorsolateral prefrontal cortex [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/24\">",
"       24",
"      </a>",
"      ], which persists even after protracted sobriety [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5974825\">",
"    <span class=\"h2\">",
"     Neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine use may lead to death of nerve cells as a consequence of multiple intracellular processes, but the evidence to date has not been conclusive.",
"   </p>",
"   <p>",
"    Research in animals suggests that human brain structures that are highly sensitive to oxidative stress, such as the hippocampus, may be affected by chronic methamphetamine use. Extensive studies in animals have shown that methamphetamine increases the blood brain barrier permeability, which most sensitively affects hippocampus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/26\">",
"     26",
"    </a>",
"    ]. Several molecular mechanisms have been proposed to contribute to methamphetamine-induced neurotoxicity, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oxidative stress, eg, free radicals in the intracellular space",
"     </li>",
"     <li>",
"      Excitotoxic mechanisms, eg, excessive glutamate",
"     </li>",
"     <li>",
"      Neuroinflammation, eg, inflammation of the glia",
"     </li>",
"     <li>",
"      Ubiquitin proteasome system, dysfunctional recycling of proteins",
"     </li>",
"     <li>",
"      Mitochondrial dysfunction, eg, abnormal carbohydrate metabolism",
"     </li>",
"     <li>",
"      Neurotrophic factor dysfunction, eg, altered growth or development of neurons and glia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Changes in the blood brain barrier may enable the entry of pathogens into the brain parenchyma, thus decreasing the endogenous brain repair resources [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of the human brain of individuals with a history of polydrug abuse (not necessarily including stimulants) have found extensive evidence of neurotoxicity; however, postmortem human data regarding the effects of methamphetamine on monoamine neurotoxicity in humans are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/19\">",
"     19",
"    </a>",
"    ]. Systematic histological, immunohistochemical, and morphometric studies of the brains of individuals with polydrug abuse have shown profound neuronal loss, neurodegenerative alterations, a reduction of glial fibrillary acidic protein-immunopositive astrocytes, widespread axonal damage with concomitant microglial activation, and changes in microvasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/28\">",
"     28",
"    </a>",
"    ]. Some but not all of these findings have been noted in postmortem studies of brains of methamphetamine users [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93519205\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical effects of methamphetamine use are almost immediate, in part due to the routes of administration. The drug has been found most often to be smoked (68 percent) or snorted (31 percent), and less commonly to be injected (7 percent) or orally ingested (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methamphetamine rapidly enters well-perfused organs, including the brain, and has a half-life of approximately 9 to 13 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/32\">",
"     32",
"    </a>",
"    ]. Methamphetamine can accumulate in the brain in concentrations up to 10 times greater than those in the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute behavioral effects of methamphetamine include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased energy and alertness",
"     </li>",
"     <li>",
"      Decreased need for sleep",
"     </li>",
"     <li>",
"      Euphoria",
"     </li>",
"     <li>",
"      Increased sexuality",
"     </li>",
"     <li>",
"      Excessive talking",
"     </li>",
"     <li>",
"      Sweating",
"     </li>",
"     <li>",
"      Disrupted sleep patterns",
"     </li>",
"     <li>",
"      Tightened jaw muscles",
"     </li>",
"     <li>",
"      Grinding teeth",
"     </li>",
"     <li>",
"      Loss of appetite, contributing to weight loss with chronic use",
"     </li>",
"     <li>",
"      Disorganized thinking",
"     </li>",
"     <li>",
"      Itching",
"     </li>",
"     <li>",
"      GI symptoms such as nausea, vomiting, or diarrhea",
"     </li>",
"     <li>",
"      Dry mouth leading to serious tooth decay with chronic use",
"     </li>",
"     <li>",
"      Changes in mood consisting of irritability, anxiety, aggression, or panic",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599083730\">",
"    <span class=\"h2\">",
"     Psychosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated 8 to 27 percent of individuals using methamphetamine experience methamphetamine-induced psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/35\">",
"     35",
"    </a>",
"    ]. The predominant symptoms are paranoia, persecutory delusions, auditory, visual, and tactile hallucinations. Methamphetamine associated psychosis is characterized by relatively long duration of psychosis and recurrence without relapse to the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/35-38\">",
"     35-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5974923\">",
"    <span class=\"h2\">",
"     Cognitive effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of the effect of methamphetamine use on cognition is mixed and in some dispute [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/39\">",
"     39",
"    </a>",
"    ]. Studies of the acute effects of methamphetamine have found improved cognitive performance in selected domains including visuospatial perception, attention [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/40\">",
"     40",
"    </a>",
"    ], inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/41\">",
"     41",
"    </a>",
"    ] and social-cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis found that methamphetamine abuse or dependence was associated with medium effect-size deficits in [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Episodic memory",
"     </li>",
"     <li>",
"      Executive functions",
"     </li>",
"     <li>",
"      Information processing speed",
"     </li>",
"     <li>",
"      Motor skills",
"     </li>",
"     <li>",
"      Language",
"     </li>",
"     <li>",
"      Visuoconstructional abilities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical significance of cognitive impairments associated with long-term methamphetamine use is uncertain. Cognitive functioning in methamphetamine users has been found to fall overwhelmingly within the normal range when compared against normative data [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24480277\">",
"    <span class=\"h2\">",
"     Abstinence syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals experience an early abstinence syndrome after cessation of methamphetamine use, which manifests as one or more symptoms including [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anhedonia",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Poor concentration",
"     </li>",
"     <li>",
"      Hyperphagia",
"     </li>",
"     <li>",
"      Insomnia or hypersomnia",
"     </li>",
"     <li>",
"      Psychomotor agitation or retardation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these symptoms appear to resolve within two weeks, although sleep disruption was reported to last as long as four weeks in a small sample [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/46\">",
"     46",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93519212\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a nationally representative US survey, approximately five percent of respondents who used non-prescribed stimulants were estimated to become stimulant-dependent over a two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/47\">",
"     47",
"    </a>",
"    ]. Methamphetamine users were more likely to become dependent soon after onset of use compared to users of other stimulants. Little is known about the factors that influence the transition from non-addicted use of methamphetamine to methamphetamine dependence.",
"   </p>",
"   <p>",
"    Methamphetamine addiction is often characterized by repeated periods of intense use with intermittent sobriety and relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Although there are few long-term studies, an analysis of methamphetamine use in 474 individuals with chronic use over a 10-year period following initiation found that subjects used the drug an average of approximately 12 days per month [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/50\">",
"     50",
"    </a>",
"    ]. Application of growth mixture models revealed five distinct trajectories of drug use:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing use, 15 percent",
"     </li>",
"     <li>",
"      Decreasing use, 21 percent",
"     </li>",
"     <li>",
"      High use, 22 percent",
"     </li>",
"     <li>",
"      Moderate use, 35 percent",
"     </li>",
"     <li>",
"      Low use, 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been limited study of patient characteristics associated with treatment completion or outcome. In an analysis of 113,575 outpatient or residential treatment episodes for methamphetamine abuse or dependence from 1992 to 2002, non-completion of treatment was associated with patient and clinical characteristics including [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less than a high school education",
"     </li>",
"     <li>",
"      Younger age at treatment admission",
"     </li>",
"     <li>",
"      Concurrent disability",
"     </li>",
"     <li>",
"      Greater severity of methamphetamine use prior to treatment",
"     </li>",
"     <li>",
"      Methamphetamine injection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals who inject methamphetamine have been found to have particularly poor treatment outcomes in other studies. As an example, in a study of 974 methamphetamine users in outpatient treatment, patients who injected the drug, relative to those using other routes of administration, had [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poorer treatment engagement",
"     </li>",
"     <li>",
"      Greater drug use during treatment",
"     </li>",
"     <li>",
"      Lower rates of treatment completion",
"     </li>",
"     <li>",
"      Greater methamphetamine use 12 months following treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Social pressure to use methamphetamine is a leading antecedent of relapse, based on our experience as well as a study of 60 patients in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/53\">",
"     53",
"    </a>",
"    ]. These interactions may be mediated by social adaptation, emotional stability, and education level. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93519219\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial examination of the patient should focus on the characteristics of current use, ie, the pattern, amount, and progression of recent use, and the route of administration. Given the clinical effects of methamphetamine use, the significant comorbidity of other psychiatric disorders, and the medical consequences of methamphetamine use, patients should also be assessed for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of depression, anxiety, and psychosis",
"     </li>",
"     <li>",
"      Use of other substances",
"     </li>",
"     <li>",
"      Personality disorders",
"     </li>",
"     <li>",
"      Medical conditions, including cardiovascular and central nervous system disease",
"     </li>",
"     <li>",
"      Socio-cultural context of methamphetamine use, which is important for identifying factors that might predict relapse, eg, regular contact with peers or partners who continue to use the drug. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urine toxicology tests can identify whether or not methamphetamine has been used, but no current laboratory or neuroimaging tests can be useful in diagnosing methamphetamine abuse or dependence. No clinical tests can predict outcomes of these disorders following treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2133290\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of methamphetamine abuse and dependence is made on the basis of DSM-IV-TR criteria, summarized below and shown in detail in the tables that follow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2133331\">",
"    <span class=\"h3\">",
"     Methamphetamine abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine abuse is defined as a maladaptive pattern of use within a 12-month period associated with one or more of the following (",
"    <a class=\"graphic graphic_table graphicRef74334 \" href=\"UTD.htm?27/54/28523\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to fulfill role obligations (eg, at work, school or home)",
"     </li>",
"     <li>",
"      Recurrent use in physically hazardous situations",
"     </li>",
"     <li>",
"      Recurrent legal problems related to use",
"     </li>",
"     <li>",
"      Continued use despite methamphetamine-related social or interpersonal problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2133339\">",
"    <span class=\"h3\">",
"     Methamphetamine dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine dependence is defined as a maladaptive pattern of use within a 12-month period associated with three or more of the following (",
"    <a class=\"graphic graphic_table graphicRef50295 \" href=\"UTD.htm?11/26/11692\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tolerance",
"     </li>",
"     <li>",
"      Withdrawal",
"     </li>",
"     <li>",
"      Methamphetamine taken in larger quantity than intended",
"     </li>",
"     <li>",
"      Persistent desire to cut down or control use",
"     </li>",
"     <li>",
"      Time is spent obtaining, using, or recovering from methamphetamine",
"     </li>",
"     <li>",
"      Social, occupational, or recreational tasks are sacrificed",
"     </li>",
"     <li>",
"      Use continues despite physical and psychological problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599083855\">",
"    <span class=\"h3\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a comorbid psychiatric disorder (most commonly, an anxiety, depressive, or psychotic disorder, or ADHD) may be difficult when the individual is actively using methamphetamine, because methamphetamine use can induce these symptoms. A drug-free period of at least a month is suggested before diagnosing one of one of these mental disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22920/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15336338\">",
"     'Comorbidity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2192570\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms related to methamphetamine use need to be distinguished from other mental and substance-use disorders that can present similarly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601612380\">",
"    <span class=\"h4\">",
"     Psychosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The psychotic symptoms and disorganized thinking that can be seen with methamphetamine use can be indistinguishable from an acute psychotic episode due to other causes, described below. (See",
"    <a class=\"local\" href=\"#H599083730\">",
"     'Psychosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Schizophrenia or schizoaffective disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"       \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute manic episode",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other stimulant drugs including cocaine, phencyclidine, and synthetic cathinone ('bath salts') (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"       \"Cocaine abuse and dependence in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link\">",
"       \"Phencyclidine (PCP) intoxication in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/51/20281?source=see_link\">",
"       \"Acute amphetamine and synthetic cathinone (&ldquo;bath salt&rdquo;) intoxication\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601612387\">",
"    <span class=\"h4\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of methamphetamine intoxication or withdrawal can mimic an anxiety disorder. Methamphetamine withdrawal can be difficult to distinguish from a major depressive disorder if withdrawal symptoms persist as long as two weeks.",
"   </p>",
"   <p>",
"    Differentiating a methamphetamine-use disorder from other mental or substance-use disorders can be informed by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Collateral information from individuals close to the patient",
"     </li>",
"     <li>",
"      Detailed history of prior episodes",
"     </li>",
"     <li>",
"      Urine toxicology for methamphetamine and other drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93519240\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of methamphetamine abuse and dependence has waned somewhat over the past few years; however, amphetamine-type use disorders are on the rise worldwide. (See",
"      <a class=\"local\" href=\"#H93519177\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methamphetamine has profound and multi-level effects on the dopamine system in the brain and increases the synaptic availability of this neurotransmitter following intake. (See",
"      <a class=\"local\" href=\"#H93519191\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of methamphetamine use include intense euphoria, energy, increased libido, and excessive talkativeness. Some patients experience psychotic symptoms. (See",
"      <a class=\"local\" href=\"#H93519205\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence on the effects of methamphetamine on cognitive performance is mixed. While some studies have identified neurocognitive deficits in users, their magnitude has not been clearly shown to be clinically significant. (See",
"      <a class=\"local\" href=\"#H5974923\">",
"       'Cognitive effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The course of methamphetamine abuse and dependence is prolonged and often characterized by repeated episodes of intense use, sobriety, and relapse. Individuals who inject the drug have been found to experience a worse course compared to those with other routes of administration. (See",
"      <a class=\"local\" href=\"#H93519212\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment should focus on the severity of methamphetamine use, comorbid conditions, and psychosocial factors that may contribute to future relapse. (See",
"      <a class=\"local\" href=\"#H93519219\">",
"       'Assessment and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/1\">",
"      Degenhardt L, Mathers B, Guarinieri M, et al. Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy 2010; 21:347.",
"     </a>",
"    </li>",
"    <li>",
"     Unodc. World Drug Report 2010, United Nations Publication, Vienna 2010.",
"    </li>",
"    <li>",
"     UNODC. World Drug Report 2012, Contract No: E.12.XI.1, United Nations Publication, New York 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/4\">",
"      Anglin MD, Burke C, Perrochet B, et al. History of the methamphetamine problem. J Psychoactive Drugs 2000; 32:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/5\">",
"      Durell TM, Kroutil LA, Crits-Christoph P, et al. Prevalence of nonmedical methamphetamine use in the United States. Subst Abuse Treat Prev Policy 2008; 3:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/6\">",
"      Rawson RA, Anglin MD, Ling W. Will the methamphetamine problem go away? J Addict Dis 2002; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/7\">",
"      Maxwell JC, Brecht ML. Methamphetamine: here we go again? Addict Behav 2011; 36:1168.",
"     </a>",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/9\">",
"      Gonzales R, Mooney L, Rawson RA. The methamphetamine problem in the United States. Annu Rev Public Health 2010; 31:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/10\">",
"      Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res 2011; 186:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/11\">",
"      Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/12\">",
"      Zorick T, Sugar CA, Hellemann G, et al. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug Alcohol Depend 2011; 118:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/13\">",
"      Kay-Lambkin FJ, Baker AL, Lee NM, et al. The influence of depression on treatment for methamphetamine use. Med J Aust 2011; 195:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/14\">",
"      Kuo CJ, Liao YT, Chen WJ, et al. Causes of death of patients with methamphetamine dependence: a record-linkage study. Drug Alcohol Rev 2011; 30:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/15\">",
"      Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007; 102:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/16\">",
"      Gibson DR, Leamon MH, Flynn N. Epidemiology and public health Consequences of methamphetamine use in California's Central Valley. J Psychoactive Drugs 2002; 34:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/17\">",
"      Forrest DW, Metsch LR, LaLota M, et al. Crystal methamphetamine use and sexual risk behaviors among HIV-positive and HIV-negative men who have sex with men in South Florida. J Urban Health 2010; 87:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/18\">",
"      Zapata LB, Hillis SD, Marchbanks PA, et al. Methamphetamine use is independently associated with recent risky sexual behaviors and adolescent pregnancy. J Sch Health 2008; 78:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/19\">",
"      Barr AM, Panenka WJ, MacEwan GW, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006; 31:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/20\">",
"      Wang GJ, Smith L, Volkow ND, et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 2012; 17:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/21\">",
"      Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001; 158:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/22\">",
"      Lee B, London ED, Poldrack RA, et al. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009; 29:14734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/23\">",
"      Johanson CE, Frey KA, Lundahl LH, et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 2006; 185:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/24\">",
"      Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003; 160:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/25\">",
"      Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21:9414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/26\">",
"      Martins T, Baptista S, Gon&ccedil;alves J, et al. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res 2011; 1411:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/27\">",
"      Silva AP, Martins T, Baptista S, et al. Brain injury associated with widely abused amphetamines: neuroinflammation, neurogenesis and blood-brain barrier. Curr Drug Abuse Rev 2010; 3:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/28\">",
"      B&uuml;ttner A. Review: The neuropathology of drug abuse. Neuropathol Appl Neurobiol 2011; 37:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/29\">",
"      Sekine Y, Ouchi Y, Sugihara G, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 2008; 28:5756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/30\">",
"      Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996; 2:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/31\">",
"      Wood E, Stoltz JA, Zhang R, et al. Circumstances of first crystal methamphetamine use and initiation of injection drug use among high-risk youth. Drug Alcohol Rev 2008; 27:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/32\">",
"      Fowler JS, Volkow ND, Logan J, et al. Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. Neuroimage 2008; 43:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/33\">",
"      Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis 2002; 21:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/34\">",
"      Hart CL, Gunderson EW, Perez A, et al. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 2008; 33:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/35\">",
"      Grant KM, LeVan TD, Wells SM, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol 2012; 7:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/36\">",
"      Son JH, Latimer C, Keefe KA. Impaired formation of stimulus-response, but not action-outcome, associations in rats with methamphetamine-induced neurotoxicity. Neuropsychopharmacology 2011; 36:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/37\">",
"      Dean AC, Groman SM, Morales AM, London ED. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology 2013; 38:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/38\">",
"      Morgan EE, Woods SP, Poquette AJ, et al. Visual memory in methamphetamine-dependent individuals: deficient strategic control of encoding and retrieval. Aust N Z J Psychiatry 2012; 46:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/39\">",
"      Hart CL, Marvin CB, Silver R, Smith EE. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology 2012; 37:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/40\">",
"      Price KL, DeSantis SM, Simpson AN, et al. The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina. Am J Addict 2011; 20:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/41\">",
"      Tolliver BK, Price KL, Baker NL, et al. Impaired cognitive performance in subjects with methamphetamine dependence during exposure to neutral versus methamphetamine-related cues. Am J Drug Alcohol Abuse 2012; 38:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/42\">",
"      Homer BD, Solomon TM, Moeller RW, et al. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 2008; 134:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/43\">",
"      Nestor LJ, Ghahremani DG, Monterosso J, London ED. Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects. Psychiatry Res 2011; 194:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/44\">",
"      Scott JC, Woods SP, Matt GE, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007; 17:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/45\">",
"      Newton TF, Kalechstein AD, Duran S, et al. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict 2004; 13:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/46\">",
"      Mancino MJ, Gentry BW, Feldman Z, et al. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse 2011; 37:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/47\">",
"      O'Brien MS, Anthony JC. Extra-medical stimulant dependence among recent initiates. Drug Alcohol Depend 2009; 104:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/48\">",
"      Hser YI, Evans E, Huang D, et al. Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addict Behav 2008; 33:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/49\">",
"      Brecht ML, Huang D, Evans E, Hser YI. Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug Alcohol Depend 2008; 96:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/50\">",
"      Hser YI, Huang D, Brecht ML, et al. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis 2008; 27:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/51\">",
"      Brecht ML, Greenwell L, Anglin MD. Methamphetamine treatment: trends and predictors of retention and completion in a large state treatment system (1992-2002). J Subst Abuse Treat 2005; 29:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/52\">",
"      Rawson RA, Gonzales R, Marinelli-Casey P, Ang A. Methamphetamine dependence: a closer look at treatment response and clinical characteristics associated with route of administration in outpatient treatment. Am J Addict 2007; 16:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/53\">",
"      Yen CF, Chang YP. Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents. Psychiatry Clin Neurosci 2005; 59:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22920/abstract/54\">",
"      Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61:807.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14839 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22920=[""].join("\n");
var outline_f22_24_22920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H93519240\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93519170\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93519177\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15336338\">",
"      Comorbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15336352\">",
"      Health consequences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24480181\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24480095\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24480195\">",
"      - Risky sexual behaviors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93519191\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5974825\">",
"      Neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93519205\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599083730\">",
"      Psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5974923\">",
"      Cognitive effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24480277\">",
"      Abstinence syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93519212\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93519219\">",
"      ASSESSMENT AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2133290\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2133331\">",
"      - Methamphetamine abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2133339\">",
"      - Methamphetamine dependence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H599083855\">",
"      - Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2192570\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H601612380\">",
"      Psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H601612387\">",
"      Anxiety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93519240\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14839|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/46/29420\" title=\"figure 1\">",
"      Methamphetamine structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14839|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/54/28523\" title=\"table 1\">",
"      DSM-IV-TR criteria for substance abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/26/11692\" title=\"table 2\">",
"      Criteria substance dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/51/20281?source=related_link\">",
"      Acute amphetamine and synthetic cathinone (&ldquo;bath salt&rdquo;) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=related_link\">",
"      Phencyclidine (PCP) intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_24_22921="Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis";
var content_f22_24_22921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22921/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22921/contributors\">",
"     Randi E. McCabe, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22921/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22921/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22921/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/24/22921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19509018\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific phobia is an anxiety disorder characterized by clinically significant fear of a particular object or situation that typically leads to avoidance behavior. Phobic fears include animals, insects, heights, water, enclosed places, driving, flying, seeing blood, getting an injection, and choking or vomiting.",
"   </p>",
"   <p>",
"    The phobic anxiety may be triggered by anticipation of the stimulus, actual exposure to the stimulus, and even hearing the stimulus name spoken aloud (eg, hearing the word spider for a spider phobic). The focus of fear may include disgust, danger of harm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the experience of physical symptoms in the phobic situation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic describes the epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of specific phobia in adults. Specific phobias relating to clinical procedures (eg, blood-injection-injury phobia) and other manifestations of acute procedural anxiety, are discussed separately. Specific phobia and other fears in children are also discussed separately. Pharmacotherapy and psychotherapy for specific phobia in adults are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"     \"Overview of fears and specific phobias in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6806?source=see_link\">",
"     \"Pharmacotherapy for specific phobia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=see_link\">",
"     \"Psychotherapy for specific phobia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link\">",
"     \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9512?source=see_link\">",
"     \"Treatment of acute procedure anxiety in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541295531\">",
"    <span class=\"h1\">",
"     SUBTYPES OF SPECIFIC PHOBIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five main subtypes of specific phobias as specified in the DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal (eg, dogs, cats, mice, spiders, bees, snakes, insects, birds)",
"     </li>",
"     <li>",
"      Natural environment (eg, storms, heights, water)",
"     </li>",
"     <li>",
"      Blood-injection-injury (eg, getting a needle, seeing blood, having blood taken, having a medical procedure, undergoing surgery or watching surgery) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link&amp;anchor=H2928848#H2928848\">",
"       \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\", section on 'Blood-injection-injury phobia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Situational (eg, driving, enclosed places, airplanes, public transportation, tunnels, elevators, bridges)",
"     </li>",
"     <li>",
"      Other (eg, fear of vomiting, choking, contracting a disease or illness, falling)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These subtypes of specific phobia can be included in the DSM-IV-TR diagnosis of specific phobia to provide more descriptive detail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509025\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevalence rates in the United States (US) for specific phobia range from 3.5 to 8.7 percent (12-month), and 7.7 to 12.5 percent (lifetime) in adult samples. The rates vary depending on study methodology (eg, the threshold used to determine distress and impairment) and demographic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although fears are common in children and most are transient, prevalence estimates of phobias in children are actually low although there is wide variation among findings (from 2.6 to 9.1 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"     \"Overview of fears and specific phobias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    International epidemiological studies suggest similarly high rates with lifetime prevalence estimates of specific phobia ranging from 5.2 to 6.1 percent in countries such as Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/7\">",
"     7",
"    </a>",
"    ], Oman [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/8\">",
"     8",
"    </a>",
"    ] and China [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/9\">",
"     9",
"    </a>",
"    ], to 11.5 to 12.8 percent in Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/10\">",
"     10",
"    </a>",
"    ] and Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/11\">",
"     11",
"    </a>",
"    ]. Although some research suggests that the prevalence of specific phobia may be lower in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/2\">",
"     2",
"    </a>",
"    ], a study of a representative sample of 558 70-year old Swedish adults found a one-month prevalence rate of 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/12\">",
"     12",
"    </a>",
"    ]. Prevalence rates in children and adolescents are estimated to be approximately 5 percent in community samples and 15 percent in clinical samples [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to most other anxiety disorders, specific phobias are more common in females than males. As an example, 13.8 percent of women and 4.5 percent of men met criteria for specific phobia in the study of 588 Swedish adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/12\">",
"     12",
"    </a>",
"    ]. However, sex differences vary across specific phobia subtypes and are stronger for animal type phobias and smaller for blood-injection-injury and height phobias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link&amp;anchor=H2928848#H2928848\">",
"     \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\", section on 'Blood-injection-injury phobia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 43,093 US adults, increased risk for specific phobia was associated with being female, young, and low income, while being Asian or Hispanic was associated with decreased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521715160\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common comorbidities associated with specific phobia include other anxiety disorders as well as mood disorders and alcohol dependence. In a community sample of 915 participants (age 15 to 54) with a lifetime history of specific phobia, 24.4 percent reported one phobia, 26.4 percent reported two phobias, 23.5 percent reported three phobias, 10.4 percent reported four phobias, and 17.3 percent reported more than four phobias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a nationally representative community survey of 9,282 adults in the US, the presence of specific phobia was correlated with the prevalence of social phobia, generalized anxiety disorder, posttraumatic stress disorder, separation anxiety disorder, major depressive disorder, bipolar disorder, and alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/6\">",
"     6",
"    </a>",
"    ]. Another national epidemiologic survey of 43,093 adults in the US, specific phobia was most strongly associated with other anxiety disorders (OR=6.5), panic disorder with agoraphobia (OR=14.6), social phobia (OR=7.9), generalized anxiety disorder (OR=6.0), major depressive disorder (OR=2.5), bipolar II disorder (OR=4.1), and alcohol dependence (OR=4.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"     \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509032\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of specific phobia is influenced by a complex interaction of biological, psychological, and",
"    <span class=\"nowrap\">",
"     social/environmental",
"    </span>",
"    factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509039\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific phobias tend to aggregate in families. First-degree relatives of individuals with specific phobia have an increased risk (31 percent versus 11 percent) of having the disorder compared to first-degree relatives of individuals without a history of a mental disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/16\">",
"     16",
"    </a>",
"    ]. However, the particular phobia that is transmitted is typically different although often it is from the same subtype. As an example, a parent may report a fear of dogs and a son may report a fear of snakes. Both phobias are within the animal subtype but the feared animal differs. Evidence for genetic transmission varies across phobia subtypes and is highest for blood-injection-injury phobias (59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/17\">",
"     17",
"    </a>",
"    ], and lowest for natural environment and situational phobias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link&amp;anchor=H2928848#H2928848\">",
"     \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\", section on 'Blood-injection-injury phobia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Twin studies suggest that although genetic factors seem to be important, environmental influences play a stronger role [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/19\">",
"     19",
"    </a>",
"    ]. In particular, individual-specific environmental influences such as experiencing a traumatic event in the phobic situation are an important etiological pathway whereas family-specific environmental influences (eg, shared environment) are not [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/16\">",
"     16",
"    </a>",
"    ]. The nature of the genetic contribution has yet to be specified but may be a low threshold for alarm reactions or an overactive baroreflex in the case of blood-injection-injury phobia specifically [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Genetics also play a role in the heritability of personality traits that increase vulnerability for the development of specific phobia. (See",
"    <a class=\"local\" href=\"#H19509053\">",
"     'Personality factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509046\">",
"    <span class=\"h2\">",
"     Neurobiological factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have found specific neuroanatomical pathways associated with specific phobia, including hyperactivation in the amygdala and insula, structures involved more broadly in negative emotional responses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/22\">",
"     22",
"    </a>",
"    ]. The classification of phobia subtypes is also supported by research suggesting unique underlying neural substrates associated with the animal and blood-injection-injury subtypes. In a study examining neural responses to phobia-specific stimuli in blood-injection-injury phobics, spider phobics, and healthy controls using functional magnetic resonance imaging (fMRI), spider phobics exhibited increased activation in the dorsal anterior cingulate and anterior insula compared to the other groups whereas blood-injection-injury phobics showed increased activation in the thalamus and occipto-temporo-parietal cortex compared to the other two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other research comparing phobic fear activation and non-phobic activation suggests that visually elicited phobic reactions activate object recognition areas and deactivate prefrontal areas involved in cognitive control over emotion-triggering areas (ie, amygdala), resulting in motor readiness for fight or flight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509053\">",
"    <span class=\"h2\">",
"     Personality factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that disgust sensitivity (the tendency to experience disgust in response to certain stimuli) is a developmental factor for certain animal and blood-injection-injury phobias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Anxiety sensitivity, a dispositional variable reflecting beliefs that the physical sensations of anxiety are harmful, has also been found to be elevated in specific phobia, particularly in the situational subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link&amp;anchor=H2928848#H2928848\">",
"     \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\", section on 'Blood-injection-injury phobia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509060\">",
"    <span class=\"h2\">",
"     Cognitive factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing body of information processing research reveals that individuals with specific phobia exhibit attentional biases to threat-related information, and perceptual and cognitive distortions consistent with their phobias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. It is unclear whether cognitive biases play a role in the development of the fear; however, it is generally accepted that they play an important role in maintaining the disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509068\">",
"    <span class=\"h2\">",
"     Social and environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A host of social and environmental factors may play a role in the development of specific phobias including the context of a traumatic event, stress at the time of the event (that may lead to an increased fear response), previous and subsequent exposure to a phobic stimulus, and level of support [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/21\">",
"     21",
"    </a>",
"    ]. Learning processes are of particular importance in the development of specific phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/21\">",
"     21",
"    </a>",
"    ]. Three pathways to fear development have been proposed within the context of biological constraints [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct conditioning involves experiencing a traumatic event in the phobic situation such as being hurt or frightened (eg, being bitten by a dog, being in a car accident, fainting at the sight of blood). In a retrospective study of precipitating events in the development of dental anxiety, participants identified disruptive emotional and interoceptive reactions during dental treatment as most strongly associated with the development of dental anxiety. Dental experiences involving feelings of helplessness were most strongly associated with a development of specific phobia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link&amp;anchor=H2928855#H2928855\">",
"       \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\", section on 'Dental phobia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vicarious acquisition involves observing someone behaving fearfully in the phobic situation or witnessing a traumatic event such as witnessing someone being bit by a dog or seeing a family member behave fearfully in the presence of a spider.",
"     </li>",
"     <li>",
"      Informational transmission involves learning to be fearful through information obtained verbally from others or through the media, such as hearing about someone being bitten by a shark or reading about a plane crash.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies with normal comparison groups find that learning experiences are equally common in individuals who do not have phobias suggesting that certain individuals are more likely to develop phobias after experiencing conditioning events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509075\">",
"    <span class=\"h2\">",
"     Evolutionary pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some fears emerge without any prior learning experiences and may be innate or biologically determined [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/35\">",
"     35",
"    </a>",
"    ]. This pathway may account for the substantial proportion of individuals who indicate they have had their phobia for as long as they can remember. Innate fears may be considered adaptive from an evolutionary perspective. This pathway is along the lines of Seligman&rsquo;s preparedness theory, which states that some individuals are prepared to develop some associations that lead to fear (eg, being afraid of dogs after being bitten by a dog) and not others (being afraid of flowers after being pricked by a thorn) to facilitate survival. Evidence for preparedness theory is mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One etiological model for the development of specific phobias during childhood proposes that specific learning experiences interact with normal developmental fears and genetically-based behavioral patterns, resulting in persistent fears that result in specific phobias, which are then maintained by cognitive biases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509082\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is common for the phobic fear to be present for a period of time before it becomes clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. Individuals often state that they recognize the fear is completely irrational or excessive but they are unable to control their response to the feared situation or object. The fear may be a source of embarrassment and is often accommodated by varying strategies of avoidance.",
"   </p>",
"   <p>",
"    As an example, someone with a fear of spiders may avoid situations that increase the likelihood of seeing a spider (eg, the basement, garage, backyard, and outdoor vacations). They also may attempt to control the environment to reduce spider exposure (eg, not opening the windows in summer, tucking in the end of the blanket even in hot weather, wearing long sleeve shirts and pants in summer).",
"   </p>",
"   <p>",
"    Clinically, specific phobia is not typically seen as the primary presenting problem as it is highly comorbid with other disorders that are usually the focus of attention, such as other anxiety disorders, mood disorders, and alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/37\">",
"     37",
"    </a>",
"    ]. There is some evidence that the individuals who present for treatment of their specific phobia differ from those who do not seek help in terms of the number and subtypes of specific phobias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional impairment associated with specific phobia can range from minimal to significant depending on the degree of fear, and the degree of impact in everyday life. For some people, the fear may be accommodated such that the impact in everyday life is minimized or not perceived as significant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. For others, the specific phobia can be quite impairing and even life threatening, as in the case of choking phobia (in extreme cases, an individual may avoid consuming any solid food or thick liquids) and blood-injection-injury phobia (an individual may avoid necessary medical procedures) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/37\">",
"     37",
"    </a>",
"    ]. An increased number of fears has been associated with increased disability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link&amp;anchor=H12823250#H12823250\">",
"     \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\", section on 'Clinical Manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings have been mixed on differences in impairment across phobia subtypes. Some studies find that situational and blood-injection-injury phobias are more impairing than animal or natural environment phobias, but other studies have found no differences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/11,40\">",
"     11,40",
"    </a>",
"    ]. As an example, one study in youth found that, compared to animal phobias, natural environment phobias were associated with greater somatic, anxious, and depressed symptoms, and increased social problems [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific phobia subtypes differ in various ways including age of onset, focus of fear, timing and predictability of the phobic response, physiological fear response, treatment response, impairment, and report of associated symptoms of anxiety, depression, other emotional problems, and behavioral problems [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/1,21,42,43\">",
"     1,21,42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link&amp;anchor=H12823250#H12823250\">",
"     \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\", section on 'Clinical Manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509089\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When untreated, phobias tend to be lifelong, with typical onset in mid-childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] or early adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/12\">",
"     12",
"    </a>",
"    ]. Age of onset varies depending on the type of phobia. Animal and blood-injection-injury phobias are more likely to begin in childhood; whereas, situational and natural environment phobias tend to occur in late adolescence or early adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/11,27\">",
"     11,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large representative sample of US adults with specific phobia, the mean duration of the disorder was 20 years, with only eight percent reporting receiving treatment specifically for specific phobia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of 137 women (age 18 to 25) found that 41.6 percent of individuals diagnosed with specific phobia at baseline were partially remitted, and 19 percent were fully remitted after an average of 17 months. A remitting course was associated with residual protective factors at baseline including positive mental health and life satisfaction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prognosis is excellent, particularly with exposure-based treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=see_link\">",
"     \"Psychotherapy for specific phobia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6806?source=see_link\">",
"     \"Pharmacotherapy for specific phobia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509096\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common phobias seen in clinical practice by physicians are typically those that have caused significant impairment in functioning and lifestyle (eg, driving, flying) or have an impact on health (vomiting, choking, blood-injection-injury, enclosed places). As an example, an individual who has of phobia of enclosed places will have great difficulty undergoing a needed MRI and this will come to the attention of the ordering physician.",
"   </p>",
"   <p>",
"    It is important for the evaluating clinician to recognize that the assessment procedure itself may be anxiety-provoking. Just the patient saying the phobic word aloud or reading it on paper may provoke an anxiety reaction. Thus, it is important to convey the need for assessing the problem, as well as the therapeutic benefit of addressing the fear directly.",
"   </p>",
"   <p>",
"    A thorough assessment approach should include detailed information on the following:",
"   </p>",
"   <p>",
"    Focus of anxiety in the phobic situation and reasons for avoidance &mdash; This may include fear of anticipated harm or danger (ie, plane crashing in flying phobia), physiological symptoms of anxiety (ie, fainting in blood-injection-injury phobia), and concerns about emotional control (having a panic attack and losing control in a driving phobia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link&amp;anchor=H12823250#H12823250\">",
"     \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\", section on 'Clinical Manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fear predictability &mdash; The fear response associated with specific phobia is typically invariably experienced upon exposure to the phobic stimulus.",
"     </li>",
"     <li>",
"      Range of situations feared and variables that influence fear intensity &mdash; Phobias may be associated with a single situation (eg, travelling by airplane in the case of flying phobia) or a wide range of situations related to the specific phobic fear. As an example of a fear manifested in many situations, an individual with a fear of snakes may avoid saying the word &ldquo;snake&rdquo;, watching certain nature programs on television, walking in forests, and toy stores. A host of variables may influence fear intensity and are specific to each individual&rsquo;s presentation. As an example, an individual with a driving phobia may report that the fear is influenced by time of day, degree of traffic, type of road, speed limit, weather conditions, and the presence of others in the car.",
"     </li>",
"     <li>",
"      Safety behaviors used to reduce anxiety",
"      <strong>",
"       &mdash;",
"      </strong>",
"      Safety behaviors are actions an individual takes to prevent a feared outcome from occurring or cope with a perceived threat [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. It is common for individuals with specific phobia to engage in safety behaviors to manage their fear. Overt safety behaviors include escape and avoidance. Subtle safety behaviors are more difficult to detect and may include cognitive distraction and thought suppression as well as carrying an item that is perceived to provide comfort or protection. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An individual with dog phobia may cross the street to avoid walking past a dog and may carry pepper spray for protection.",
"     </li>",
"     <li>",
"      An individual with a fear of flying may consume significant amounts of alcohol to reduce the experience of anxiety on a flight.",
"     </li>",
"     <li>",
"      An individual with a height phobia may avoid visiting people who live in apartment buildings and may also avoid looking out the window.",
"     </li>",
"     <li>",
"      An individual with a fear of thunderstorms may stay in the basement during a storm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skills deficits that may play a role in the specific phobia",
"      <strong>",
"       &mdash;",
"      </strong>",
"      This is particularly relevant for a specific phobia of driving. A person may not have adequate driving skills, especially if they have avoided driving and thus a portion of the fear may be realistic.",
"     </li>",
"     <li>",
"      Factors specific to symptom presentation in older adults",
"      <strong>",
"       &mdash;",
"      </strong>",
"      In older adults, additional factors that should be considered include the impact of age-related sensory impairments on communication of symptoms, presence of medical illnesses that may contribute to anxiety, and factors that may lead to symptom underreporting such as inability to recognize the experience of anxiety symptoms and the misattribution of anxiety to physical symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561244914\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This assessment information is important for establishing a differential diagnosis, as a number of disorders feature fear and avoidance of specific situations. To distinguish a specific phobia from other Axis I disorders, it is helpful to consider the focus of the fear, the circumscribed nature of the fear and avoidance, and whether the fear is captured by another Axis I disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561244921\">",
"    <span class=\"h3\">",
"     Agoraphobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple specific phobias may resemble agoraphobia. To distinguish these disorders, consider the focus of fear in the situation. In specific phobia, the focus of fear is on aspects of a particular situation, so multiple specific phobias will be associated with multiple fears (eg, driving is avoided for fear of an accident; elevators are avoided for fear of being stuck; outdoor places are avoided for fear of spiders). In agoraphobia, avoidance is typically across a range of situations, yet the focus of fear is the same across situations (eg, driving, elevators, and outdoor places are avoided for fear of panic symptoms or the unavailability of help if needed). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/15/10488?source=see_link\">",
"     \"Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561244928\">",
"    <span class=\"h3\">",
"     Panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic attacks may occur in both panic disorder and specific phobia. To differentiate these disorders it is helpful to consider the context of the panic attack. Panic disorder is characterized by uncued or unexpected panic attacks, whereas panic attacks within the context of specific phobia are typically cued by encountering the feared situation or stimulus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561244935\">",
"    <span class=\"h3\">",
"     Social phobia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social phobia related to discrete performance situations may be mistaken for a specific phobia (eg, public speaking or performing on stage). In this case it is important to discern the reasons for the fear and avoidance. Fears specific to being publically scrutinized, embarrassed, or negatively judged by others are subsumed under the diagnosis of social phobia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561244942\">",
"    <span class=\"h3\">",
"     Posttraumatic stress disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with posttraumatic stress disorder may avoid situations associated with the trauma, and a specific phobia may develop after experiencing a traumatic event in the phobic situation. To distinguish between these disorders, it is important to consider the constellation of symptoms reported and the range of situations avoided. For example, a person who experienced a traumatic motor vehicle accident and now avoids driving may receive a diagnosis of specific phobia of driving if the fear and avoidance are confined specifically to driving situations. However, if the person also reports reexperiencing symptoms, persistant avoidance of trauma cues, numbing of general responsiveness, and increased arousal, a diagnosis of posttraumatic stress disorder may be warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561244949\">",
"    <span class=\"h3\">",
"     Separation anxiety disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both specific phobia and separation anxiety disorder are associated with situational avoidance. Consideration of the focus of fear is helpful in distinguishing these two disorders. In separation anxiety disorder, situations are avoided for fear of being separated from an attachment figure or for fear of harm befalling an attachment figure. In specific phobia, fear and avoidance are related to a circumscribed situation or object and is unrelated to the",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of an attachment figure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"     \"Overview of fears and specific phobias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561244956\">",
"    <span class=\"h3\">",
"     Hypochondriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fear of illness may characterize both hypochondriasis and specific phobia, other type (fear of contracting an illness). In this instance it is important to understand the nature and context of the fear and avoidance. If the focus of fear is on having a serious illness based on misinterpretation of physical symptoms, then a diagnosis of hypochondriasis is warranted. If the focus of fear is on contracting an illness and avoidance is associated with stimuli that may lead to development of an illness, then a diagnosis of specific phobia, other type is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561244963\">",
"    <span class=\"h3\">",
"     Eating disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fear and avoidance of specific foods may characterize both eating disorders and specific phobia, other type (fear of choking). In this case, it is helpful to determine the focus of fear and reasons for avoidance. If certain foods are feared and avoided due to concerns of weight gain, then a diagnosis of eating disorder may be warranted. If certain foods are feared and avoided due to concerns of choking, then a diagnosis of specific phobia, other type (fear of choking) may be warranted. In both cases, consequent weight loss may be substantial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561245055\">",
"    <span class=\"h2\">",
"     Determining subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases, assigning the phobia subtype descriptor is straightforward. However, this is not always the case. As an example, fear of driving over a bridge may represent a height phobia (natural environment subtype) or a fear of bridges (situational subtype). The information gathered by a thorough assessment will help make the determination. If the person fears driving over the bridge because it is high and also avoids other situations consistent with a height phobia, a separate diagnosis of specific phobia of bridges would not be warranted. However, if the person fears getting stuck on the bridge (eg, having nowhere to pull over if there is car trouble or fears driving over the side), then a phobia of bridges (natural environment) is warranted. Interestingly, there is evidence that height phobias may be better classified as situational phobias given their shared clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H541295531\">",
"     'Subtypes of specific phobia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561245080\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR criteria for specific phobia are outlined in (",
"    <a class=\"graphic graphic_table graphicRef81555 \" href=\"UTD.htm?38/54/39787\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/2\">",
"     2",
"    </a>",
"    ]. To establish a diagnosis, seven criteria must be met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of excessive fear triggered by a circumscribed object or situation",
"     </li>",
"     <li>",
"      Exposure to the stimulus evokes an immediate anxiety response that may take the form of a panic attack",
"     </li>",
"     <li>",
"      The individual recognizes that the fear is excessive or unreasonable",
"     </li>",
"     <li>",
"      The phobic situation is avoided or endured with intense anxiety or distress",
"     </li>",
"     <li>",
"      The fear causes significant distress",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interference in daily functioning",
"     </li>",
"     <li>",
"      The phobia must be present for at least six months in individuals under the age of 18",
"     </li>",
"     <li>",
"      The fear must not be better accounted for by another Axis I mental disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a person has a significant fear but does not encounter the phobic situation and is not distressed by the fear, then a diagnosis of specific phobia would not be warranted. For example, a person who has a fear of fish, but does not live by a body of water, does not encounter fish in the course of daily living, and is not bothered by having the fear would not receive a specific phobia diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561245094\">",
"    <span class=\"h2\">",
"     Other diagnostic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific phobia needs to be distinguished from normative states of fear. Unlike normative fear, phobic fear [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is excessive and out of proportion to situational demands",
"     </li>",
"     <li>",
"      Cannot be alleviated with rational explanation",
"     </li>",
"     <li>",
"      Is out of voluntary control",
"     </li>",
"     <li>",
"      Leads to situational avoidance",
"     </li>",
"     <li>",
"      Is maladaptive and persistent over time",
"     </li>",
"     <li>",
"      Is not age or stage-specific",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cultural beliefs, values, and traditions may play a role in fear expression, with research showing that fears may differ in both their nature and intensity across different ethnic groups residing within the same country [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, it is important to consider the cultural context when conducting an assessment of fears. As an example, if an individual reports fear of a particular animal, but is raised within a cultural context where that fear is normative, one should not consider the fear to be excessive or unreasonable unless it is over and above the cultural norm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509103\">",
"    <span class=\"h2\">",
"     Specific phobia in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations and diagnosis of specific phobia differ in some respects in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=see_link\">",
"     \"Overview of fears and specific phobias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509110\">",
"    <span class=\"h1\">",
"     ASSESSMENT TOOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic interviews and self-report measures are useful for determining a diagnosis, screening, gathering detailed information on anxiety, and assessing symptom intensity and severity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) standard version [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/52\">",
"       52",
"      </a>",
"      ] includes dimensional ratings of fear and avoidance for 17 objects or situations from the five DSM-IV phobia subtypes. There is also a Child and Parent version available [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/53\">",
"       53",
"      </a>",
"      ]. This instrument is extremely useful for thoroughly assessing the presence of specific phobia. Although an individual may have a specific phobia, they are unlikely to report it unless they are asked. The downside of this measure is that it is time consuming and thus is best used with an individual presenting with significant anxiety as the primary problem.",
"     </li>",
"     <li>",
"      There are self-report measures specific to subtypes of specific phobia (",
"      <a class=\"graphic graphic_table graphicRef65262 \" href=\"UTD.htm?13/42/13995\">",
"       table 2",
"      </a>",
"      ). These measures are useful for determining the range of symptoms, establishing initial symptom severity and for measuring treatment progress and outcome.",
"     </li>",
"     <li>",
"      The behavioral approach task (BAT) involves having the individual confront the feared situation so that the clinician can assess fear intensity, variables that affect fear intensity, phenomenology of the anxiety response, anxious cognitions, and safety behaviors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22921/abstract/14\">",
"       14",
"      </a>",
"      ]. This method of assessment is most relevant in a setting where treatment will be provided, as it is useful for treatment planning purposes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509338\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific phobia is an anxiety disorder characterized by clinically significant anxiety associated with anticipation of, or exposure to, a circumscribed situation or object that often leads to avoidant behavior and results in considerable distress and impairment in functioning. (See",
"      <a class=\"local\" href=\"#H19509018\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The five subtypes of specific phobic are animal, natural environment, blood-injection-injury, situational, and other. The blood-injection-injury subtype is associated with a vasovagal fainting response that differentiates it from the other subtypes. (See",
"      <a class=\"local\" href=\"#H541295531\">",
"       'Subtypes of specific phobia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link\">",
"       \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Specific phobia is among the most common mental disorders, associated with high rates of comorbidity. (See",
"      <a class=\"local\" href=\"#H19509025\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complex interaction of factors contribute to the development of specific phobia including genetics, functional neuroanatomical pathways, personality factors such as anxiety sensitivity and disgust sensitivity, cognitive processing of threat-related information, and",
"      <span class=\"nowrap\">",
"       social/environmental",
"      </span>",
"      factors with",
"      <span class=\"nowrap\">",
"       learning/conditioning",
"      </span>",
"      processes having a central role. (See",
"      <a class=\"local\" href=\"#H19509032\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific phobia is not typically seen as the primary presenting problem in clinical settings. Clinical attention is usually focused on common comorbid disorders such as other anxiety disorders, mood disorders, and alcohol dependence. (See",
"      <a class=\"local\" href=\"#H19509082\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be assessed for the presence of specific phobia given the significant impairment and disability that may be associated with the disorder, as well as the low likelihood that the concern will be disclosed without prompting (possibly due to embarrassment, symptom accommodation, or priority of presenting concerns). (See",
"      <a class=\"local\" href=\"#H19509082\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/1\">",
"      LeBeau RT, Glenn D, Liao B, et al. Specific phobia: a review of DSM-IV specific phobia and preliminary recommendations for DSM-V. Depress Anxiety 2010; 27:148.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/3\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/4\">",
"      Stinson FS, Dawson DA, Patricia Chou S, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2007; 37:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/5\">",
"      Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; :21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/6\">",
"      Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/7\">",
"      Cho MJ, Kim JK, Jeon HJ, et al. Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults. J Nerv Ment Dis 2007; 195:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/8\">",
"      Jaju S, Al-Adawi S, Al-Kharusi H, et al. Prevalence and age-of-onset distributions of DSM IV mental disorders and their severity among school going Omani adolescents and youths: WMH-CIDI findings. Child Adolesc Psychiatry Ment Health 2009; 3:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/9\">",
"      Chou KL. Specific phobia in older adults: evidence from the national epidemiologic survey on alcohol and related conditions. Am J Geriatr Psychiatry 2009; 17:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/10\">",
"      Kirmizioglu Y, Doan O, Kuu N, Aky&uuml;z G. Prevalence of anxiety disorders among elderly people. Int J Geriatr Psychiatry 2009; 24:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/11\">",
"      Becker ES, Rinck M, T&uuml;rke V, et al. Epidemiology of specific phobia subtypes: findings from the Dresden Mental Health Study. Eur Psychiatry 2007; 22:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/12\">",
"      Sigstr&ouml;m R, &Ouml;stling S, Karlsson B, et al. A population-based study on phobic fears and DSM-IV specific phobia in 70-year olds. J Anxiety Disord 2011; 25:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/13\">",
"      Ollendick TH, King NJ, Muris P. Fears and phobias in children: phenomenology, epidemiology, and aetiology. Child and Adolescent Mental Health 2002; 7:98.",
"     </a>",
"    </li>",
"    <li>",
"     McCabe, RE, Ashbaugh, AR, Antony, MM. Specific and social phobias. In: Handbook of Assessment and Treatment Planning for Psychological Disorders, 2nd Ed. Antony, MM, Barlow, DH. (Eds), Guilford Press, New York 2010. p. 186.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/15\">",
"      Curtis GC, Magee WJ, Eaton WW, et al. Specific fears and phobias. Epidemiology and classification. Br J Psychiatry 1998; 173:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/16\">",
"      Fyer AJ, Mannuzza S, Gallops MS, et al. Familial transmission of simple phobias and fears. A preliminary report. Arch Gen Psychiatry 1990; 47:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/17\">",
"      Kendler KS, Karkowski LM, Prescott CA. Fears and phobias: reliability and heritability. Psychol Med 1999; 29:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/18\">",
"      Skre I, Onstad S, Torgersen S, et al. The heritability of common phobic fear: a twin study of a clinical sample. J Anxiety Disord 2000; 14:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/19\">",
"      Skre I, Onstad S, Torgersen S, et al. A twin study of DSM-III-R anxiety disorders. Acta Psychiatr Scand 1993; 88:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/20\">",
"      Adler PS, France C, Ditto B. Baroreflex sensitivity at rest and during stress in individuals with a history of vasovagal syncope. J Psychosom Res 1991; 35:591.",
"     </a>",
"    </li>",
"    <li>",
"     McCabe, RE, Antony, MM. Anxiety disorders: Social and specific phobias. In: Psychiatry third edition Tasman, A, Kay, J, Lieberman, JA, et al. (Eds), John Wiley &amp; Sons, Ltd, Chichester 2008. p. 1409.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/22\">",
"      Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 2007; 164:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/23\">",
"      Caseras X, Mataix-Cols D, Trasovares MV, et al. Dynamics of brain responses to phobic-related stimulation in specific phobia subtypes. Eur J Neurosci 2010; 32:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/24\">",
"      Ahs F, Pissiota A, Michelg&aring;rd A, et al. Disentangling the web of fear: amygdala reactivity and functional connectivity in spider and snake phobia. Psychiatry Res 2009; 172:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/25\">",
"      Sawchuk CN, Lohr JM, Tolin DF, et al. Disgust sensitivity and contamination fears in spider and blood-injection-injury phobias. Behav Res Ther 2000; 38:753.",
"     </a>",
"    </li>",
"    <li>",
"     Woody, SR, Teachman, BA. Intersection of disgust and fear: Normative and pathological views. Clin Psychol Sci Pract. 2000; 7:291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/27\">",
"      Antony MM, Brown TA, Barlow DH. Response to hyperventilation and 5.5% CO2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Am J Psychiatry 1997; 154:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/28\">",
"      Rachman S, Cuk M. Fearful distortions. Behav Res Ther 1992; 30:583.",
"     </a>",
"    </li>",
"    <li>",
"     Kindt, M, Brosschot, JF. Cognitive bias in spider-phobic children: Comparison of a pictorial and a linguistic spider Stroop. J Psychopathol Behav Assess 1999; 21:207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/30\">",
"      Jones MK, Menzies RG. Danger expectancies, self-efficacy and insight in spider phobia. Behav Res Ther 2000; 38:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/31\">",
"      Rachman S. The conditioning theory of fear-acquisition: a critical examination. Behav Res Ther 1977; 15:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/32\">",
"      Oosterink FM, de Jongh A, Aartman IH. Negative events and their potential risk of precipitating pathological forms of dental anxiety. J Anxiety Disord 2009; 23:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/33\">",
"      Hofmann SG, Ehlers A, Roth WT. Conditioning theory: a model for the etiology of public speaking anxiety? Behav Res Ther 1995; 33:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/34\">",
"      Menzies RG, Parker L. The origins of height fear: an evaluation of neoconditioning explanations. Behav Res Ther 2001; 39:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/35\">",
"      Poulton R, Menzies RG. Non-associative fear acquisition: a review of the evidence from retrospective and longitudinal research. Behav Res Ther 2002; 40:127.",
"     </a>",
"    </li>",
"    <li>",
"     Muris, P, Merckelbach, H. The etiology of childhood specific phobia: A multifactorial model. In: The Developmental Psychopathology of Anxiety, Vasey, MW, Dadds, MR (Eds), Oxford University Press, New York 2001. p.355.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/37\">",
"      Zimmerman M, Mattia JI. Principal and additional DSM-IV disorders for which outpatients seek treatment. Psychiatr Serv 2000; 51:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/38\">",
"      Chapman TF, Fyer AJ, Mannuzza S, Klein DF. A comparison of treated and untreated simple phobia. Am J Psychiatry 1993; 150:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/39\">",
"      Goisman RM, Allsworth J, Rogers MP, et al. Simple phobia as a comorbid anxiety disorder. Depress Anxiety 1998; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/40\">",
"      Depla MF, ten Have ML, van Balkom AJ, de Graaf R. Specific fears and phobias in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 2008; 43:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/41\">",
"      Ollendick TH, Raishevich N, Davis TE 3rd, et al. Specific phobia in youth: phenomenology and psychological characteristics. Behav Ther 2010; 41:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/42\">",
"      Antony MM, Brown TA, Barlow DH. Heterogeneity among specific phobia types in DSM-IV. Behav Res Ther 1997; 35:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/43\">",
"      Kim SJ, Kim BN, Cho SC, et al. The prevalence of specific phobia and associated co-morbid features in children and adolescents. J Anxiety Disord 2010; 24:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/44\">",
"      Trumpf J, Becker ES, Vriends N, et al. Rates and predictors of remission in young women with specific phobia: a prospective community study. J Anxiety Disord 2009; 23:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/45\">",
"      Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev 2008; 28:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/46\">",
"      Hood HK, Antony MM, Koerner N, Monson CM. Effects of safety behaviors on fear reduction during exposure. Behav Res Ther 2010; 48:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/47\">",
"      Salkovskis PM, Clark DM, Hackmann A, et al. An experimental investigation of the role of safety-seeking behaviours in the maintenance of panic disorder with agoraphobia. Behav Res Ther 1999; 37:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/48\">",
"      Coelho CM, Gon&ccedil;alves DC, Purkis H, et al. Specific phobias in older adults: characteristics and differential diagnosis. Int Psychogeriatr 2010; 22:702.",
"     </a>",
"    </li>",
"    <li>",
"     Marks IM. Fears and phobias, Academic Press, New York 1969.",
"    </li>",
"    <li>",
"     Miller LC, Barrett CL, Hampe E. Phobias of childhood in a prescientific era. In: Child personality and psychopathology: Current topics, Davids A (Ed), Wiley, New York 1974. p.89.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22921/abstract/51\">",
"      Meltzer H, Vostanis P, Dogra N, et al. Children's specific fears. Child Care Health Dev 2009; 35:781.",
"     </a>",
"    </li>",
"    <li>",
"     Brown, TA, Di Nardo, PA, Barlow, DH. Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV). Oxford University Press, New York 1994.",
"    </li>",
"    <li>",
"     Silverman, WK, Albano, AM. Anxiety disorders interview schedule for DSM-IV, child and parent versions. Psychological Corporation. San Antonio 1996.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14637 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-42E0F5FCD1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22921=[""].join("\n");
var outline_f22_24_22921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19509338\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19509018\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541295531\">",
"      SUBTYPES OF SPECIFIC PHOBIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19509025\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521715160\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19509032\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509039\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509046\">",
"      Neurobiological factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509053\">",
"      Personality factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509060\">",
"      Cognitive factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509068\">",
"      Social and environmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509075\">",
"      Evolutionary pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19509082\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19509089\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19509096\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H561244914\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561244921\">",
"      - Agoraphobia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561244928\">",
"      - Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561244935\">",
"      - Social phobia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561244942\">",
"      - Posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561244949\">",
"      - Separation anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561244956\">",
"      - Hypochondriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561244963\">",
"      - Eating disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H561245055\">",
"      Determining subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H561245080\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H561245094\">",
"      Other diagnostic considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509103\">",
"      Specific phobia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19509110\">",
"      ASSESSMENT TOOLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19509338\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/54/39787\" title=\"table 1\">",
"      DSM-IV-TR criteria for specific phobia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/42/13995\" title=\"table 2\">",
"      Self-report measures for specific phobia by phobia subtype",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=related_link\">",
"      Acute procedure anxiety in adults: Epidemiology and clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/15/10488?source=related_link\">",
"      Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30808?source=related_link\">",
"      Overview of fears and specific phobias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6806?source=related_link\">",
"      Pharmacotherapy for specific phobia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=related_link\">",
"      Psychotherapy for specific phobia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9512?source=related_link\">",
"      Treatment of acute procedure anxiety in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_24_22922="Granuloma annulare";
var content_f22_24_22922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Granuloma annulare",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22922/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22922/contributors\">",
"     Robert Brodell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22922/contributors\">",
"     Erik Stratman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/24/22922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/24/22922/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/24/22922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H35143160\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;First described in 1895 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/1\">",
"     1",
"    </a>",
"    ], granuloma annulare (GA) is a relatively common, often self-limited disorder that can affect both children and adults. Localized GA, which classically presents as a nonscaly, erythematous, annular plaque on the distal extremity is the most common form of GA. The generalized form of GA, which accounts for approximately 15 percent of cases, typically presents with numerous erythematous papules and plaques on the trunk and extremities. Less common forms of GA include subcutaneous, perforating, and patch variants.",
"   </p>",
"   <p>",
"    Many cases of GA resolve spontaneously within a few years, and treatment is only indicated for patients who have symptomatic lesions or cosmetic concerns. Localized lesions are usually treated with topical or intralesional corticosteroids. Options for the treatment of generalized GA include topical therapies, phototherapy, and systemic medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143167\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence of GA is unknown, but it has been estimated that approximately 0.1 to 0.4 percent of new patients who present to dermatologists have GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/2\">",
"     2",
"    </a>",
"    ]. Localized GA most frequently occurs during the first three decades of life, although it is not limited to this demographic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, generalized GA frequently presents during the fourth to seventh decades.",
"   </p>",
"   <p>",
"    Subcutaneous GA, patch GA, and perforating GA are less common manifestations of this disorder. Subcutaneous GA is most common in children, while the patch type has primarily been reported in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/4\">",
"     4",
"    </a>",
"    ]. Perforating GA is a rare variant that may occur in both adults and children, and appears to have an increased prevalence in the Hawaiian islands [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, women appear to be at increased risk for GA. Among cases of localized GA, the ratio of females to males is estimated to be approximately 2.5 to 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/2\">",
"     2",
"    </a>",
"    ]. A retrospective study of 100 patients with generalized GA also noted a female predominance; the ratio of females to males was 2.9 to 1 among patients with predominantly annular lesions, and 1.4 to 1 among patients with generalized papular GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143174\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the cause of GA is unknown, a variety of potential inciting factors have been reported, including trauma, insect bites, tuberculin skin testing, vaccinations, sun exposure, and various viral infections (eg, hepatitis B, hepatitis C, Epstein-Barr virus, HIV) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/7\">",
"     7",
"    </a>",
"    ]. Multiple cases in which GA developed within scars from herpes zoster have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The relationship between GA and systemic diseases remains unclear. (See",
"    <a class=\"local\" href=\"#H19690202\">",
"     'Associated disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is also uncertain whether genetic factors influence susceptibility to GA. Familial cases have been documented, but studies investigating associations of the disease with human leukocyte antigen (HLA) genes have yielded inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Increased frequency of HLA-B35 in patients with generalized GA has been reported in two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A dermal lymphohistiocytic infiltrate and degenerated collagen are typical histopathologic findings in GA, and may offer clues to the pathogenesis of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/16\">",
"     16",
"    </a>",
"    ]. A delayed-type hypersensitivity reaction in which Th1 lymphocytes stimulate macrophages to express proinflammatory cytokines and collagen-degrading enzymes may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/17\">",
"     17",
"    </a>",
"    ]. Injury to dermal elastic fibers has also been proposed as an inciting factor for GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/18\">",
"     18",
"    </a>",
"    ]. Immune-mediated vasculitis was thought to be a contributing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/19\">",
"     19",
"    </a>",
"    ]; however, subsequent studies have not identified vasculitis as a prominent feature in GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143181\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;GA can present with a variety of clinical findings. Shared histopathologic features support the classification of these clinical variants into a single disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143190\">",
"    <span class=\"h2\">",
"     Localized GA",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the most common form of GA, localized GA classically presents as an asymptomatic, skin-colored or erythematous, annular or arciform plaque with a moderately firm, rope-like border and central clearing (",
"    <a class=\"graphic graphic_picture graphicRef76216 graphicRef62354 graphicRef73823 graphicRef62598 \" href=\"UTD.htm?30/16/30986\">",
"     picture 1A-D",
"    </a>",
"    ). Discrete 1 to 2 mm papules may be noted at the periphery of lesions that have not developed a continuous border. In a minority of cases, papules may also be present centrally (",
"    <a class=\"graphic graphic_picture graphicRef61039 \" href=\"UTD.htm?40/17/41233\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lesions of localized GA typically grow slowly in a centrifugal pattern; most lesions are less than 5 cm in size [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/2\">",
"     2",
"    </a>",
"    ]. The most frequent locations for localized GA are the wrists, ankles, dorsal hands, and dorsal feet. Involvement of the palms is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/20\">",
"     20",
"    </a>",
"    ]. Approximately 50 percent of patients will have more than one lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infrequently, localized GA may also present as clusters of small papules without an annular or arcuate configuration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143197\">",
"    <span class=\"h2\">",
"     Generalized GA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized GA presents with widespread, skin-colored to erythematous papules and plaques, ranging from millimeters to a few centimeters in diameter (",
"    <a class=\"graphic graphic_picture graphicRef71308 graphicRef77002 graphicRef51459 graphicRef64223 graphicRef53172 graphicRef53898 \" href=\"UTD.htm?37/58/38826\">",
"     picture 3A-F",
"    </a>",
"    ). Annular plaques are present in up to two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. The trunk and extremities are prominent sites of involvement in generalized GA, while the head, neck, palms, soles, and mucous membranes are generally spared. Involved skin may be asymptomatic or pruritic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143204\">",
"    <span class=\"h2\">",
"     Subcutaneous GA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single or multiple, deep dermal or subcutaneous, painless nodules on the scalp or extremities are the hallmark of subcutaneous GA (",
"    <a class=\"graphic graphic_picture graphicRef65614 \" href=\"UTD.htm?28/0/28672\">",
"     picture 4",
"    </a>",
"    ). The skin overlying the nodules appears normal. Lesions of subcutaneous GA are usually less than 4 cm in size and are most commonly located on the anterior lower legs, hands, head, and buttocks of children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143218\">",
"    <span class=\"h2\">",
"     Perforating GA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforating GA is a variant of GA in which damaged collagen from the dermis is extruded onto the skin surface. This variant, which is most commonly seen in children and young adults, is characterized by asymptomatic erythematous papules that evolve into yellowish umbilicated papules that discharge clear or white fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/5\">",
"     5",
"    </a>",
"    ]. Some lesions may resemble pustules. Perforating GA may be localized (usually on the extremities) or widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/2\">",
"     2",
"    </a>",
"    ]. Pruritus or pain is present in a minority of patients. Lesions heal with scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19689471\">",
"    <span class=\"h2\">",
"     Patch GA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the patch type of GA present with annular or nonannular, nonscaly patches that may be localized or generalized (",
"    <a class=\"graphic graphic_picture graphicRef75365 \" href=\"UTD.htm?36/23/37232\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/4,24,25\">",
"     4,24,25",
"    </a>",
"    ]. Lesions commonly involve the proximal extremities. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67047128\">",
"    <span class=\"h2\">",
"     Other variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the established variants, GA has been reported to occur in a linear pattern and as uncharacteristically painful papules and plaques on acral skin.",
"   </p>",
"   <p>",
"    Linear presentations of GA have been documented in a few patients (",
"    <a class=\"graphic graphic_picture graphicRef65976 \" href=\"UTD.htm?41/14/42208\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In one of these cases, the lesion appeared following venectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute, painful, erythematous papules or plaques on the hands and feet with histopathologic findings consistent with GA were reported in four patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/29\">",
"     29",
"    </a>",
"    ]. Arthralgias accompanied symptoms in two of the patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19690202\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19690225\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data conflict on whether there is an association between diabetes mellitus and GA. In general, studies investigating this link have been of poor design and have been compromised by methodological flaws.",
"   </p>",
"   <p>",
"    One retrospective study of 557 patients with GA found a higher incidence of insulin-dependent diabetes than expected when compared to data from an age-matched population (16 actual verus 0.9 expected cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/30\">",
"     30",
"    </a>",
"    ]. All but one patient with diabetes in this study had localized GA. In contrast, another retrospective study reported a higher incidence of diabetes (type unspecified) among 100 patients with generalized GA than among 1350 patients with localized GA (21 versus 10 percent had diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/6\">",
"     6",
"    </a>",
"    ]. A third retrospective study of 84 patients suggested that diabetes may influence disease course in GA; patients with diabetes (n = 10) appeared to have more chronic, relapsing courses of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between diabetes and GA was refuted by the authors of a case-control study that compared 50 patients with GA (type unspecified) to 50 patients with psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/32\">",
"     32",
"    </a>",
"    ]. No significant difference in the prevalence of diabetes mellitus was noted between the two groups. Of note, more recent evidence linking psoriasis to metabolic syndrome raises questions about whether psoriasis patients were an appropriate control population for this study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43001?source=see_link&amp;anchor=H896745#H896745\">",
"     \"Comorbid disease in psoriasis\", section on 'Metabolic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective study of 23 patients that assessed HgbA1C levels in 23 patients with GA (13 localized, 10 generalized) also did not support an association between these disorders; normal HgbA1C levels were detected in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the relationship between diabetes and GA remains uncertain. Future well-designed studies are necessary to explore this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19690232\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain whether GA portends an increased risk for malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. A review of 16 case reports and two retrospective studies published between 1966 and 2001 was unable to identify a definitive relationship between malignancy and GA, but noted that cases linked to malignancy typically occurred in patients with an atypical presentation of GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/34\">",
"     34",
"    </a>",
"    ]. Lymphoma was the most common association, accounting for approximately 50 percent of malignancies. Cancers were diagnosed between 18 months before and 42 months after a diagnosis of GA. Based upon these findings, the authors suggested evaluating older adults with atypical clinical presentations of GA for underlying malignancy.",
"   </p>",
"   <p>",
"    Complicating the interpretation of the literature is the concern that some cases of GA that have been associated with malignancy may have been cases of interstitial granulomatous dermatitis (IGD) that were misdiagnosed. IGD can clinically and histologically resemble GA and has been associated with the development of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H33#H33\">",
"     \"Neutrophilic dermatoses\", section on 'Palisaded neutrophilic granulomatous dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622572\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;GA may be associated with dyslipidemia. In a case-control study of 140 adults with idiopathic GA and 420 controls, dyslipidemia was significantly more prevalent among adults with GA (79 versus 52 percent; adjusted odds ratio 4.04, 95% CI 2.53-6.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/37\">",
"     37",
"    </a>",
"    ]. The highest rates of dyslipidemia were seen with generalized GA (all of 23 patients) and GA with annular lesions (65 of 76 patients [86 percent]).",
"   </p>",
"   <p>",
"    The rationale for an association between GA and dyslipidemia is unclear. Theories on the mechanism of the association include the possibility of an effect of chronic inflammation related to GA on the development of lipid abnormalities and the possibility that microvascular inflammation and dysfunction due to dyslipidemia contributes to GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/37\">",
"     37",
"    </a>",
"    ]. Additional studies on the relationship between GA and dyslipidemia are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636707\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports have linked GA to thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. There have also been multiple reports of GA in the setting of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. In a series of 34 patients with both HIV and GA, the generalized variant of GA was most common, occurring in approximately 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143232\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lymphohistiocytic infiltrate, degeneration of collagen, and mucin deposition are characteristic histopathologic features of GA; these findings often present in an interstitial or palisaded pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/16,45,46\">",
"     16,45,46",
"    </a>",
"    ]. The interstitial pattern occurs in approximately 70 percent of cases, while a palisading pattern is seen in about 25 percent of biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/45\">",
"     45",
"    </a>",
"    ]. Mucin deposition can be highlighted with alcian blue or colloidal iron stains.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The interstitial pattern is characterized by histiocytes embedded in basophilic mucin infiltrating between collagen bundles in the mid to upper dermis. Incomplete degeneration of collagen fibers is present (",
"      <a class=\"graphic graphic_picture graphicRef67442 \" href=\"UTD.htm?36/43/37560\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The palisading pattern is characterized by lymphohistiocytic inflammatory infiltrates that palisade around foci of collagen and elastin degeneration in the mid to upper dermis. Areas of collagen degeneration appear as eosinophilic fibrillar material separated by basophilic mucin deposits (",
"      <a class=\"graphic graphic_picture graphicRef74645 graphicRef76130 graphicRef54717 \" href=\"UTD.htm?40/45/41690\">",
"       picture 8A-C",
"      </a>",
"      )",
"      <strong>",
"       .",
"      </strong>",
"      Eosinophils may also be present.",
"     </li>",
"     <li>",
"      Rarely, epithelioid histiocytic nodules resembling findings in sarcoidosis can be seen in GA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=see_link\">",
"       \"Cutaneous manifestations of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both the interstitial and palisading patterns can occur in localized and generalized GA. The interstitial pattern typically is associated with patch type GA; subcutaneous GA frequently presents with large histiocytic palisades surrounding degenerated collagen and mucin in the connective tissue septae within the subcutis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/23\">",
"     23",
"    </a>",
"    ]. Perforating GA shows transepidermal elimination of mucinous, degenerating collagen fibers surrounded by palisading lymphohistiocytic granulomas (",
"    <a class=\"graphic graphic_picture graphicRef56210 \" href=\"UTD.htm?43/8/44167\">",
"     picture 9",
"    </a>",
"    )",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Necrobiosis lipoidica diabeticorum and rheumatoid nodules can present with histopathologic features similar to the palisading necrobiotic granulomas of GA. Histopathologic features that can assist with distinguishing these disorders from GA include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Necrobiosis lipoidica diabeticorum",
"      </strong>",
"      &ndash; Broad areas of necrobiosis that sometimes extend into the subcutis are present within the superficial and deep dermis. Lipid deposits are visible within areas of necrobiosis and mucin deposition is absent.",
"     </li>",
"     <li>",
"      <strong>",
"       Rheumatoid nodule",
"      </strong>",
"      &ndash; Rheumatoid nodules are difficult to distinguish from GA histopathologically. Sharp, irregular areas of necrobiosis are present within the subcutis and deep reticular dermis. Acute or chronic endoarteritis adjacent to the necrobiotic foci is evident in some cases. Unlike GA, mucin is usually absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143239\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of the classic clinical features of localized GA is usually sufficient for diagnosis; the presence of an asymptomatic, nonscaly, erythematous, annular or arcuate plaque with peripheral papules and central clearing is characteristic of localized GA. A biopsy is useful for atypical presentations or when the diagnosis is in question. A potassium hydroxide (KOH) preparation or fungal culture should be performed when the differential diagnosis includes a dermatophyte infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The widespread nature and variable lesion morphology in generalized GA contributes to the need for a punch biopsy to confirm the diagnosis in most cases.",
"   </p>",
"   <p>",
"    The lack of overlying cutaneous changes can make a clinical diagnosis of subcutaneous GA difficult; an excisional biopsy should be performed when the diagnosis is in question.",
"   </p>",
"   <p>",
"    No serologic tests are useful for the diagnosis of GA. Although further study is needed to confirm the findings of the case-control study that found an association between GA and dyslipidemia in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/37\">",
"     37",
"    </a>",
"    ], due to the risks associated with dyslipidemia, we typically obtain a lipid profile in adults who present with GA. Laboratory studies to evaluate for the presence of other associated diseases is unnecessary for most patients. Patients with GA should be asked about signs or symptoms of diabetes mellitus, and if present, screening tests should be performed. Patients with GA who have risk factors or symptoms suggestive of HIV infection should be tested for this infection. Routine testing for other infectious disorders usually is not indicated, except as suggested by patient symptoms or signs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Age-appropriate cancer screening should be performed in elderly patients with atypical clinical presentations of GA or other patients who present with signs of symptoms suggestive of malignancy (eg, unexplained weight loss, night sweats).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19689888\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other skin conditions may mimic the clinical findings in GA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19689903\">",
"    <span class=\"h2\">",
"     Annular lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annular lesions similar to those seen in localized or generalized GA may also occur in other disorders (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35688?source=see_link\">",
"     \"Approach to the patient with annular skin lesions\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tinea corporis",
"      </strong>",
"      &ndash; Absence of scale is a key feature of GA that distinguishes it from tinea corporis on clinical examination (",
"      <a class=\"graphic graphic_picture graphicRef53271 \" href=\"UTD.htm?3/24/3459\">",
"       picture 10",
"      </a>",
"      ). A KOH preparation or fungal culture can be used to confirm tinea infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"       \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Annular lichen planus",
"      </strong>",
"      &ndash; The detection of characteristic violaceous, polygonal, pruritic papules at the periphery of annular lesions of lichen planus can help to distinguish this disorder from GA. Rounded, erythematous non-pruritic papules are more consistent with GA. The penis and scrotum are common sites of involvement in annular lichen planus (",
"      <a class=\"graphic graphic_picture graphicRef76913 \" href=\"UTD.htm?12/48/13059\">",
"       picture 11",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link\">",
"       \"Lichen planus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cutaneous sarcoidosis",
"      </strong>",
"      &ndash; Sarcoidosis may present with widespread, flesh-colored papules and annular plaques (",
"      <a class=\"graphic graphic_picture graphicRef53918 \" href=\"UTD.htm?8/38/8803\">",
"       picture 12",
"      </a>",
"      ). Histopathology revealing naked granulomas will distinguish sarcoidosis from GA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=see_link\">",
"       \"Cutaneous manifestations of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Annular elastolytic giant cell granuloma (AEG, actinic granuloma)",
"      </strong>",
"      &ndash; Lesions of AEG appear as annular erythematous patches on sun-exposed skin (",
"      <a class=\"graphic graphic_picture graphicRef51388 graphicRef65166 \" href=\"UTD.htm?42/29/43478\">",
"       picture 13A-B",
"      </a>",
"      ). A biopsy of AEG reveals giant cells phagocytizing elastic fibers in the dermis; necrobiosis and palisading granulomas may be present. Loss and fragmentation of elastic fibers in the dermis and the absence of mucin are characteristic histopathologic features that distinguish this disorder from GA.",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema annulare centrifugum (EAC)",
"      </strong>",
"      &ndash; Superficial or deep EAC usually presents with multiple annular, erythematous plaques (",
"      <a class=\"graphic graphic_picture graphicRef80998 graphicRef59741 \" href=\"UTD.htm?10/33/10774\">",
"       picture 14A-B",
"      </a>",
"      ). The characteristic rim of scale along the inner margin of the lesion that occurs in superficial EAC (&ldquo;trailing scale&rdquo;) is not present in GA. However, scale is often absent in deep EAC. Histopathologic findings distinguish this disorder from GA; a distinctive dense lymphocytic infiltrate surrounding blood vessels is present in EAC.",
"     </li>",
"     <li>",
"      <strong>",
"       Interstitial",
"      </strong>",
"      <strong>",
"       granulomatous dermatitis (IGD)",
"      </strong>",
"      &ndash; IGD has been associated with autoimmune disease, malignancy, and medications. This disorder often presents with erythematous annular plaques favoring the lateral trunk and skin folds (",
"      <a class=\"graphic graphic_picture graphicRef52974 \" href=\"UTD.htm?28/11/28862\">",
"       picture 15",
"      </a>",
"      ). Like GA, degenerated collagen and palisading histiocytes are histopathologic features of IGD. The presence of neutrophils and an absence of mucin are useful for distinguishing this disorder from GA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H33#H33\">",
"       \"Neutrophilic dermatoses\", section on 'Palisaded neutrophilic granulomatous dermatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nodular tertiary syphilis",
"      </strong>",
"      &ndash; Rarely, cutaneous tertiary syphilis may present as annular plaques [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/50\">",
"       50",
"      </a>",
"      ]. Plasma cells and granulomas on biopsy suggest this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67046911\">",
"    <span class=\"h2\">",
"     Other lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of cutaneous diseases may resemble the other manifestations of GA. Biopsy often is helpful for distinguishing GA from these disorders.",
"   </p>",
"   <p>",
"    Lesions of",
"    <strong>",
"     generalized papular GA",
"    </strong>",
"    may resemble:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary syphilis (",
"      <a class=\"graphic graphic_picture graphicRef60313 \" href=\"UTD.htm?12/22/12642\">",
"       picture 16",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H13#H13\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Secondary syphilis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Id (autoeczematous) reactions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=see_link&amp;anchor=H14#H14\">",
"       \"Contact dermatitis in children\", section on 'Autoeczematization'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H4733135#H4733135\">",
"       \"Dermatophyte (tinea) infections\", section on 'Dermatophytid (id) reactions'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Arthropod bites (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link&amp;anchor=H2#H2\">",
"       \"Insect bites\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eruptive xanthomas (",
"      <a class=\"graphic graphic_picture graphicRef82268 \" href=\"UTD.htm?31/38/32353\">",
"       picture 17",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to the patient with hypertriglyceridemia\", section on 'Disorders of triglyceride metabolism'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eruptive histiocytomas",
"     </li>",
"     <li>",
"      Eruptive syringomas (",
"      <a class=\"graphic graphic_picture graphicRef71531 graphicRef79695 \" href=\"UTD.htm?41/63/42998\">",
"       picture 18A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Subcutaneous GA",
"    </strong>",
"    has a broad clinical differential diagnosis including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatoid nodules (histopathology may closely resemble GA) (",
"      <a class=\"graphic graphic_picture graphicRef74194 \" href=\"UTD.htm?28/4/28737\">",
"       picture 19",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link\">",
"       \"Rheumatoid nodules\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epithelioid sarcoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"       \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subcutaneous sarcoidosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=see_link&amp;anchor=H29997403#H29997403\">",
"       \"Cutaneous manifestations of sarcoidosis\", section on 'Subcutaneous sarcoidosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Deep fungal or bacterial infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Perforating GA",
"    </strong>",
"    may mimic other disorders in which dermal contents are eliminated through the epidermis. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reactive perforating collagenosis",
"     </li>",
"     <li>",
"      Perforating folliculitis (",
"      <a class=\"graphic graphic_picture graphicRef62671 graphicRef72434 \" href=\"UTD.htm?41/8/42119\">",
"       picture 20A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Elastosis perforans serpiginosa (",
"      <a class=\"graphic graphic_picture graphicRef53188 \" href=\"UTD.htm?22/63/23551\">",
"       picture 21",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Perforating cutaneous sarcoidosis (histopathologic features may closely resemble GA) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The umbilicated shape and white central core noted in some lesions of molluscum contagiosum may also resemble perforating GA (",
"    <a class=\"graphic graphic_picture graphicRef55247 \" href=\"UTD.htm?13/9/13461\">",
"     picture 22",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=see_link&amp;anchor=H6#H6\">",
"     \"Molluscum contagiosum\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patch GA may resemble parapsoriasis, which presents with large, erythematous patches on the trunk and proximal extremities (",
"    <a class=\"graphic graphic_picture graphicRef68028 \" href=\"UTD.htm?32/12/32963\">",
"     picture 23",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/25\">",
"     25",
"    </a>",
"    ]. Fine scale, when present, suggests a diagnosis of parapsoriasis. Biopsy confirms the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345299\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143253\">",
"    <span class=\"h2\">",
"     Localized GA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized GA is generally asymptomatic and self-limited. For many patients, no treatment is necessary. However, since the lesions may persist for two years or more and can be cosmetically distressing or occasionally symptomatic, some patients desire therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20262888\">",
"    <span class=\"h3\">",
"     First-line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;High potency topical corticosteroids or intralesional corticosteroids are the most common treatments prescribed for localized GA. Although evidence for the efficacy of these agents is primarily limited to documentation of clinical experience, corticosteroids are used as first-line interventions because they are easily administered and are relatively safe when used properly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20262895\">",
"    <span class=\"h4\">",
"     Topical or intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment with topical or intralesional corticosteroids has been documented in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, the response to treatment is variable. In a retrospective study of patients with GA, topical corticosteroids were effective in 8 patients and ineffective in 26; however, the type and potency of topical corticosteroids used were not specified [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/6\">",
"     6",
"    </a>",
"    ]. The same authors noted more frequent success with intralesional corticosteroids. Out of 14 patients who were given intralesional therapy, treatment was effective in 11 (79 percent).",
"   </p>",
"   <p>",
"    Although needleless injectors are not typically used for treatment, the results of an early nonrandomized study (n = 45) utilizing this modality also support the efficacy of intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    for GA; 68 percent of patients had a complete response to injection of triamcinolone acetonide compared with 44 percent of patients who received intralesional normal saline [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/53\">",
"     53",
"    </a>",
"    ]. The statistical significance of these results was not assessed in the study.",
"   </p>",
"   <p>",
"    The discomfort associated with intralesional injection may be a deterrent to this therapy in children and some adults. For patients who prefer to avoid intralesional treatment, we typically prescribe a superpotent topical corticosteroid such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05% cream or spray (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). The corticosteroid should be applied once daily with an occlusive dressing, or twice daily if occlusion is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/51\">",
"     51",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/55/20340?source=see_link\">",
"     Flurandrenolide",
"    </a>",
"    tape (an occlusive tape impregnated with a superpotent topical corticosteroid) can also be used for treatment.",
"   </p>",
"   <p>",
"    Once or twice daily application of the topical corticosteroid should continue for at least two to four weeks prior to assessing for a response. Once significant improvement is noted, the frequency of application can be tapered, followed by discontinuation when signs of disease activity are absent. If there is no response after four to eight weeks of treatment, the patient should be reassessed and alternative treatments, such as intralesional corticosteroids, should be considered.",
"   </p>",
"   <p>",
"    For patients who can tolerate intralesional corticosteroid injection, we typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide in concentrations of 2.5 to 10",
"    <span class=\"nowrap\">",
"     mg/cc.",
"    </span>",
"    A 30-gauge needle is used to inject 0.1 cc of the mixture into the border of a lesion; when multiple injections are required, injection sites should be separated by approximately 5 to 10 mm. Injections are repeated every six to eight weeks as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential side effects of topical and intralesional corticosteroids include cutaneous atrophy, telangiectasias, and hypopigmentation. Patients should be followed closely for the development of these adverse effects. Systemic absorption leading to adrenal suppression is a risk when large skin areas are treated, making local corticosteroid therapy less favorable for the management of patients with generalized disease. In general, the total dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide given in one treatment session should not exceed 40 mg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link&amp;anchor=H7#H7\">",
"     \"Intralesional injection\", section on 'Side effects, complications, and pitfalls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20262978\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other therapies have been used for localized GA, including cryotherapy, light-based therapies, and additional topical or intralesional agents. Evidence for the efficacy of these agents is limited.",
"   </p>",
"   <p>",
"    The efficacy of cryotherapy was investigated in an uncontrolled study of 28 patients with GA.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    or liquid nitrogen applied with a closed probe led to lesion resolution in 81 percent of patients; relapse was noted in only 1 out of 11 patients who were followed for at least two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/54\">",
"     54",
"    </a>",
"    ]. However, atrophic scarring, hypopigmentation, or hyperpigmentation occurred in 21 percent of study participants, and an excellent cosmetic result was reported in only 50 percent. Although it has not been formally studied, liquid nitrogen administered via a spray canister is used by some dermatologists. In our clinical experience, the response to this technique is variable.",
"   </p>",
"   <p>",
"    Various forms of phototherapy may have some benefit in the treatment of localized GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/55-61\">",
"     55-61",
"    </a>",
"    ]. In an uncontrolled study of five patients with GA, topical psoralen plus UVA light (PUVA) four times per week for a mean of 26 treatments led to clearance of lesions in four patients and significant improvement in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/55\">",
"     55",
"    </a>",
"    ]. Follow-up was short; reevaluation after four months did not show recurrence of disease. However, relapse has been reported following PUVA therapy in patients with other forms of GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. PUVA also has been linked to the onset of GA in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement with UVA1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/57\">",
"     57",
"    </a>",
"    ], a narrowband UVB light source [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/58\">",
"     58",
"    </a>",
"    ], and targeted broadband UVB phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/59\">",
"     59",
"    </a>",
"    ] has also been reported. Photodynamic therapy was evaluated in a series of seven patients with localized GA; two patients each had complete clearance or marked clearance of disease, and three patients did not respond to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapies used for localized GA have included topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/65\">",
"     65",
"    </a>",
"    ], topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20308?source=see_link\">",
"     recombinant human interferon gamma",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/68\">",
"     68",
"    </a>",
"    ], and pulsed dye laser [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Topical tacrolimus has been reported to be effective in two patients who failed treatment with medium to high potency topical corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/65\">",
"     65",
"    </a>",
"    ]; however, improvement with topical corticosteroids following failure with tacrolimus has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/52\">",
"     52",
"    </a>",
"    ]. A case in which a lesion of GA worsened after treatment with imiquimod has also occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143260\">",
"    <span class=\"h2\">",
"     Generalized GA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the appearance of generalized GA and the intractable pruritus that is sometimes associated with this disorder can be psychologically disabling, there have been no randomized trials of treatments for generalized GA. Evidence is limited for all of the treatment options below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H880145\">",
"    <span class=\"h3\">",
"     First-line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapies and phototherapy are first-line treatments for GA based upon the available evidence for the efficacy of these agents and the low risk of serious adverse effects with these treatments. However, the application of topical therapy to numerous lesions can be difficult for some patients. In addition, the restricted availability, high cost, and frequent office visits associated with phototherapy make systemic medications a reasonable alternative for some patients with extensive GA. (See",
"    <a class=\"local\" href=\"#H880137\">",
"     'Systemic therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346142\">",
"    <span class=\"h4\">",
"     Topical or intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to localized GA, topical or intralesional corticosteroids may lead to improvement of individual lesions in the generalized variant. However, when used in widespread GA, clinicians should be cognizant of the potential for local and systemic adverse effects. Treatment with topical or intralesional corticosteroids is most beneficial for treating select lesions in patients with generalized GA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346111\">",
"    <span class=\"h4\">",
"     Topical calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series of four patients with disseminated GA, twice daily application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1% ointment for six weeks led to complete clearance in two patients and marked improvement in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/72\">",
"     72",
"    </a>",
"    ]. Fading of lesions was noted within the first 10 to 21 days of treatment. Relapse did not occur during a six-week follow-up period.",
"   </p>",
"   <p>",
"    Application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    cream for three months led to clearance of face and neck lesions, and significant improvement in body lesions in a patient who failed treatment with topical corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/73\">",
"     73",
"    </a>",
"    ]. Improvement persisted six months after the completion of therapy.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Unlike topical corticosteroids, risks of cutaneous atrophy and adrenal suppression are not associated with the use of topical calcineurin inhibitors. Although the risk for malignancy appears to be minimal, the US Food and Drug Administration (FDA) has placed a &ldquo;black box&rdquo; warning on topical calcineurin inhibitors due to concern for the potential of these agents to increase the risk for internal malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20263475\">",
"    <span class=\"h4\">",
"     UVA1 phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of UVA1 phototherapy is primarily limited to academic centers.",
"   </p>",
"   <p>",
"    The initial report of UVA1 for generalized GA documented marked improvement in four patients treated with this modality (cumulative dose of UVA1 = 1840",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/74\">",
"     74",
"    </a>",
"    ]. However, responses to treatment have been less consistent in subsequent studies in which patients received lower cumulative doses of UVA1. In an uncontrolled, prospective study of patients with long-standing disseminated GA, 16 patients were treated with high dose UVA1 (median treatment dose 110",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    median total dose of 1770",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and four patients were treated with medium dose UVA1 (median treatment dose 50",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    median total dose 890",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/75\">",
"     75",
"    </a>",
"    ]. Nine patients (56 percent) in the high dose group and one patient (25 percent) in the medium dose group achieved substantial improvement or near complete clearance of disease. However, seven out of nine patients for whom follow-up data were available relapsed after the cessation of therapy (median time to relapse = 3 months).",
"   </p>",
"   <p>",
"    A subsequent retrospective study of UVA1 phototherapy for a variety of skin diseases reported modest benefit of UVA1 in generalized GA. Out of 20 patients treated with UVA1 (mean treatment dose of 75",
"    <span class=\"nowrap\">",
"     J/cm2,",
"    </span>",
"    mean total dose 1352 J), seven patients had mild improvement, three had moderate improvement, and three marked improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/76\">",
"     76",
"    </a>",
"    ]. No patients achieved complete remission.",
"   </p>",
"   <p>",
"    Although UVA1 appears to have some efficacy for generalized GA, further studies are necessary to identify the optimal treatment regimen. Acute adverse effects of UVA1 include erythema, pruritus, and reactivation of herpes simplex virus infection. The long term risk for skin cancer with UVA1 remains uncertain; however, this modality is generally considered to be less carcinogenic than PUVA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20263482\">",
"    <span class=\"h4\">",
"     Photochemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PUVA has shown efficacy for generalized GA in published reports of small numbers of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. A study of five patients, including one patient with perforating lesions, showed flattening as early as one month after the start of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/62\">",
"     62",
"    </a>",
"    ]. All patients were clear of disease within three to four months. Although relapse recurred after the discontinuation of treatment, patients responded to retreatment. Another study showed clearing of three patients in 6 to 12 months, but only one patient had a durable remission [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with PUVA has been associated with the development of cutaneous malignancies. However, the risk of this appears to be most prominent in patients who receive long-term therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H10#H10\">",
"     \"Risk factors for the development of melanoma\", section on 'PUVA therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'UVA radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Therapeutic exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H880137\">",
"    <span class=\"h3\">",
"     Systemic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple systemic drugs have been used in the treatment of generalized GA. We most commonly use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    due to the efficacy and relative safety of these medications. Due to the potential severe adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , its use should be limited to patients with severe, refractory disease. Treatment with systemic medications is generally discontinued once a satisfactory response is attained.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      <strong>",
"       (3 to 6",
"       <span class=\"nowrap\">",
"        mg/kg/day)",
"       </span>",
"      </strong>",
"      &ndash; The efficacy of hydroxychloroquine in disseminated GA is supported by a series of six children who were treated with 3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      of hydroxychloroquine [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/81\">",
"       81",
"      </a>",
"      ]. Complete clearance of disease occurred within four to six weeks in all patients. No recurrences were reported during a mean follow-up period of two years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/81\">",
"       81",
"      </a>",
"      ]. Successful treatment also has been reported in other patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/6,82,83\">",
"       6,82,83",
"      </a>",
"      ]. Improvement is usually noted within one to two months with hydroxychloroquine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       Isotretinoin",
"      </a>",
"      <strong>",
"       (0.5",
"       <span class=\"nowrap\">",
"        mg/kg/day)",
"       </span>",
"      </strong>",
"      &ndash; Treatment with isotretinoin has been associated with resolution of generalized GA in several case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/84-89\">",
"       84-89",
"      </a>",
"      ]. Some patients have had remissions lasting for more than six months, while others have relapsed after the discontinuation of treatment. Isotretinoin is usually given for three to four months. The drug is contraindicated in pregnancy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      <strong>",
"       (100",
"       <span class=\"nowrap\">",
"        mg/day)",
"       </span>",
"      </strong>",
"      &ndash; In one series of six patients, all showed complete clearing of disease with dapsone; four remained clear at a follow-up visit between 4 and 20 months after the cessation of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/90\">",
"       90",
"      </a>",
"      ]. An uncontrolled study also reported benefit with dapsone, but noted higher rates of relapse following the discontinuation of therapy. In the study, 7 out of 10 patients with generalized GA responded to treatment (four complete responses and three partial responses), but all relapsed within three months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/91\">",
"       91",
"      </a>",
"      ]. Treatment durations with dapsone generally range between a few weeks and four months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      <strong>",
"       (3 to 4",
"       <span class=\"nowrap\">",
"        mg/kg/day)",
"       </span>",
"      </strong>",
"      &ndash; Cyclosporine has been effective in case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/93-97\">",
"       93-97",
"      </a>",
"      ]. Some patients have relapsed following cyclosporine therapy, while others have had remissions lasting at least one year. Doses of cyclosporine have ranged from 3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      The potential adverse effects of this agent (renal failure, malignancy, hepatotoxicity, hypertension, and infections) limit its use to patients with severe, refractory disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nicotinamide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/98\">",
"     98",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/99\">",
"     99",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/100-102\">",
"     100-102",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/103\">",
"     103",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/104\">",
"     104",
"    </a>",
"    ], and fumaric acid esters [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/105,106\">",
"     105,106",
"    </a>",
"    ] have led to improvement in generalized GA in case reports. Clinical benefit has also been documented in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/107\">",
"     107",
"    </a>",
"    ] or a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346393\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement of generalized GA following photodynamic therapy or fractional photothermolysis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19690484\">",
"    <span class=\"h2\">",
"     Other GA variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment usually is not necessary for subcutaneous GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/111\">",
"     111",
"    </a>",
"    ]. Although excisional biopsy of one lesion is useful for diagnosis, surgery for treatment of this benign condition usually is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/22,111-113\">",
"     22,111-113",
"    </a>",
"    ]. Recurrence is common following surgical excision, and spontaneous resolution occurs in 50 percent of patients within two years.",
"   </p>",
"   <p>",
"    Treatments similar to those used in the more common localized and generalized manifestations of GA can be attempted in patients with patch or perforating GA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/4,114\">",
"     4,114",
"    </a>",
"    ]. Resolution in patch GA following biopsy was reported in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/115\">",
"     115",
"    </a>",
"    ]. Response to treatment in perforating GA often is disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143267\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No preventive measures have been proven to be effective in GA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143274\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fifty percent of cases of localized GA resolve within two years, but recurrence is possible. As resolution occurs, the papules at the periphery recede. Blanchable macular erythema remains for months until the lesions completely disappear without scarring. Recurrences tend to appear in the same areas as the original lesions. Eighty percent of recurrent lesions resolve within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generalized GA may persist or clear spontaneously. In a retrospective review of 100 patients with generalized GA, at least 25 percent had disease courses of greater than five years, and at least 10 percent had persistent disease after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/24/22922/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/23/35185?source=see_link\">",
"       \"Patient information: Granuloma annulare (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35143281\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granuloma annulare (GA) is a benign cutaneous skin disorder that may affect both adults and children. The cause of GA is unknown. (See",
"      <a class=\"local\" href=\"#H35143167\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35143174\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GA may present with a variety of clinical findings. The most common types of GA are the localized and generalized forms. Additional variants of GA include subcutaneous, perforating, and patch GA. (See",
"      <a class=\"local\" href=\"#H35143181\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localized GA classically presents as a nonscaly, annular or arcuate inflammatory plaque on a distal extremity. Generalized GA presents with widely distributed papules and plaques on the trunk and extremities. Pruritus may accompany generalized GA. (See",
"      <a class=\"local\" href=\"#H35143190\">",
"       'Localized GA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35143197\">",
"       'Generalized GA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relationships between GA and diabetes mellitus, dyslipidemia, and internal malignancy are not well understood. Additional studies are necessary to determine whether there is a link between GA and these disorders. (See",
"      <a class=\"local\" href=\"#H19690202\">",
"       'Associated disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical examination often is sufficient for the diagnosis of localized GA. Unlike tinea corporis, scale is always absent. Skin biopsies assist with distinguishing the other variants of GA from skin disorders with similar clinical features. No serologic tests are useful to confirm the diagnosis of GA. (See",
"      <a class=\"local\" href=\"#H35143239\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because it is unknown whether there is a relationship between diabetes and GA, patients who present with GA should be asked about signs and symptoms of diabetes. Routine screening for diabetes in all patients is not necessary. The possibility of malignancy should be investigated in older adults who present with atypical presentations of GA. (See",
"      <a class=\"local\" href=\"#H35143239\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with localized GA who desire treatment, we suggest treatment with topical or intralesional corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients should be followed closely for the development of cutaneous adverse effects. Other treatment options include cryotherapy, phototherapy, and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H35143253\">",
"       'Localized GA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with generalized GA who desire treatment, we suggest treatment with topical calcineurin inhibitors, UVA1, or PUVA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If treatment with topical calcineurin inhibitors or phototherapy is impractical or ineffective, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical corticosteroids can be useful for treating select lesions in generalized GA. (See",
"      <a class=\"local\" href=\"#H35143260\">",
"       'Generalized GA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with GA experience spontaneous resolution of disease within a few years. In a minority of cases, disease can persist for more than a decade.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/1\">",
"      Fox TC. Ringed eruption of the fingers. Br J Dermatol 1895; 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/2\">",
"      Muhlbauer JE. Granuloma annulare. J Am Acad Dermatol 1980; 3:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/3\">",
"      Rapelanoro-Rabenja F, Maleville J, Ta&iuml;eb A. [Localized granuloma annulare in children: outcome in 30 cases]. Arch Pediatr 1995; 2:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/4\">",
"      Mutasim DF, Bridges AG. Patch granuloma annulare: clinicopathologic study of 6 patients. J Am Acad Dermatol 2000; 42:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/5\">",
"      Samlaska CP, Sandberg GD, Maggio KL, Sakas EL. Generalized perforating granuloma annulare. J Am Acad Dermatol 1992; 27:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/6\">",
"      Dabski K, Winkelmann RK. Generalized granuloma annulare: clinical and laboratory findings in 100 patients. J Am Acad Dermatol 1989; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     Prendiville, JS. Granuloma annulare. In: Fitzpatrick's Dermatology in General Medicine, 7th ed., Woff, K, Goldsmith, LA, Katz, SI, et al. (Eds), McGraw-Hill Companies, Inc., 2008. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/8\">",
"      Mahajan S, Koranne RV, Sharma SK. Cutaneous manifestation of diabetes mellitus. Indian J Dermatol Venereol Leprol 2003; 69:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/9\">",
"      Chang SE, Bae GY, Moon KC, et al. Subcutaneous granuloma annulare following herpes zoster. Int J Dermatol 2004; 43:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/10\">",
"      Ruocco E, Baroni A, Cutr&igrave; FT, Filioli FG. Granuloma annulare in a site of healed herpes zoster: Wolf's isotopic response. J Eur Acad Dermatol Venereol 2003; 17:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/11\">",
"      Ohata C, Shirabe H, Takagi K, Kawatsu T. Granuloma annulare in herpes zoster scars. J Dermatol 2000; 27:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/12\">",
"      Friedman SJ, Winkelmann RK. Familial granuloma annulare. Report of two cases and review of the literature. J Am Acad Dermatol 1987; 16:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/13\">",
"      ROOK A, DAVIS R, STEVANOVIC D. Familial granuloma annulare; report of two cases, with observations on the incidence of the disease in Britain. Acta Derm Venereol 1957; 37:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/14\">",
"      Friedman-Birnbaum R, Haim S, Gideone O, Barzilai A. Histocompatibility antigens in granuloma annulare. Comparative study of the generalized and localized types. Br J Dermatol 1978; 98:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/15\">",
"      Friedman-Birnbaum R, Gideoni O, Bergman R, Pollack S. A study of HLA antigen association in localized and generalized granuloma annulare. Br J Dermatol 1986; 115:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/16\">",
"      G&uuml;ne P, G&ouml;ktay F, Mansur AT, et al. Collagen-elastic tissue changes and vascular involvement in granuloma annulare: a review of 35 cases. J Cutan Pathol 2009; 36:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/17\">",
"      Fayyazi A, Schweyer S, Eichmeyer B, et al. Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch Dermatol Res 2000; 292:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/18\">",
"      Hanna WM, Moreno-Merlo F, Andrighetti L. Granuloma annulare: an elastic tissue disease? Case report and literature review. Ultrastruct Pathol 1999; 23:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/19\">",
"      Dahl MV. Speculations on the pathogenesis of granuloma annulare. Australas J Dermatol 1985; 26:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/20\">",
"      Hsu S, Lehner AC, Chang JR. Granuloma annulare localized to the palms. J Am Acad Dermatol 1999; 41:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/21\">",
"      Yun JH, Lee JY, Kim MK, et al. Clinical and pathological features of generalized granuloma annulare with their correlation: a retrospective multicenter study in Korea. Ann Dermatol 2009; 21:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/22\">",
"      Felner EI, Steinberg JB, Weinberg AG. Subcutaneous granuloma annulare: a review of 47 cases. Pediatrics 1997; 100:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/23\">",
"      Requena L, Fern&aacute;ndez-Figueras MT. Subcutaneous granuloma annulare. Semin Cutan Med Surg 2007; 26:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/24\">",
"      Victor FC, Mengden S. Granuloma annulare, patch type. Dermatol Online J 2008; 14:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/25\">",
"      Coelho R, Carvalho R, Rodrigues A, et al. Patch-type granuloma annulare. Eur J Dermatol 2009; 19:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/26\">",
"      Borgia F, Cannav&ograve; SP, Guarneri F, et al. Isomorphic response after saphenectomy in a patient with granuloma annulare. J Am Acad Dermatol 2004; 50:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/27\">",
"      Harpster EF, Mauro T, Barr RJ. Linear granuloma annulare. J Am Acad Dermatol 1989; 21:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/28\">",
"      Morice-Picard F, Boralevi F, Lepreux S, et al. Severe linear form of granuloma annulare along Blaschko's lines preceding the onset of a classical form of granuloma annulare in a child. Br J Dermatol 2007; 157:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/29\">",
"      Brey NV, Malone J, Callen JP. Acute-onset, painful acral granuloma annulare: a report of 4 cases and a discussion of the clinical and histologic spectrum of the disease. Arch Dermatol 2006; 142:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/30\">",
"      Muhlemann MF, Williams DR. Localized granuloma annulare is associated with insulin-dependent diabetes mellitus. Br J Dermatol 1984; 111:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/31\">",
"      Studer EM, Calza AM, Saurat JH. Precipitating factors and associated diseases in 84 patients with granuloma annulare: a retrospective study. Dermatology 1996; 193:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/32\">",
"      Nebesio CL, Lewis C, Chuang TY. Lack of an association between granuloma annulare and type 2 diabetes mellitus. Br J Dermatol 2002; 146:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/33\">",
"      Gannon TF, Lynch PJ. Absence of carbohydrate intolerance in granuloma annulare. J Am Acad Dermatol 1994; 30:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/34\">",
"      Li A, Hogan DJ, Sanusi ID, Smoller BR. Granuloma annulare and malignant neoplasms. Am J Dermatopathol 2003; 25:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/35\">",
"      Dahl MV. Granuloma annulare: long-term follow-up. Arch Dermatol 2007; 143:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/36\">",
"      Hawryluk EB, Izikson L, English JC 3rd. Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions. Am J Clin Dermatol 2010; 11:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/37\">",
"      Wu W, Robinson-Bostom L, Kokkotou E, et al. Dyslipidemia in granuloma annulare: a case-control study. Arch Dermatol 2012; 148:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/38\">",
"      V&aacute;zquez-L&oacute;pez F, Gonz&aacute;lez-L&oacute;pez MA, Raya-Aguado C, P&eacute;rez-Oliva N. Localized granuloma annulare and autoimmune thyroiditis: a new case report. J Am Acad Dermatol 2000; 43:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/39\">",
"      Kappeler D, Troendle A, Mueller B. Localized granuloma annulare associated with autoimmune thyroid disease in a patient with a positive family history for autoimmune polyglandular syndrome type II. Eur J Endocrinol 2001; 145:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/40\">",
"      Tursen U, Pata C, Kaya TI, et al. Generalized granuloma annulare associated with Plummer's disease. J Eur Acad Dermatol Venereol 2002; 16:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/41\">",
"      Toro JR, Chu P, Yen TS, LeBoit PE. Granuloma annulare and human immunodeficiency virus infection. Arch Dermatol 1999; 135:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/42\">",
"      O'Moore EJ, Nandawni R, Uthayakumar S, et al. HIV-associated granuloma annulare (HAGA): a report of six cases. Br J Dermatol 2000; 142:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/43\">",
"      McGregor JM, McGibbon DH. Disseminated granuloma annulare as a presentation of acquired immunodeficiency syndrome (AIDS). Clin Exp Dermatol 1992; 17:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/44\">",
"      Kapembwa MS, Goolamali SK, Price A, Boyle S. Granuloma annulare masquerading as molluscum contagiosum-like eruption in an HIV-positive African woman. J Am Acad Dermatol 2003; 49:S184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/45\">",
"      Umbert P, Winkelmann RK. Histologic, ultrastructural and histochemical studies of granuloma annulare. Arch Dermatol 1977; 113:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/46\">",
"      Dabski K, Winkelmann RK. Generalized granuloma annulare: histopathology and immunopathology. Systematic review of 100 cases and comparison with localized granuloma annulare. J Am Acad Dermatol 1989; 20:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/47\">",
"      Spencer SA, Fenske NA, Espinoza CG, et al. Granuloma annulare-like eruption due to chronic Epstein-Barr virus infection. Arch Dermatol 1988; 124:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/48\">",
"      Winkelmann RK. The granuloma annulare phenotype and tuberculosis. J Am Acad Dermatol 2002; 46:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/49\">",
"      Granel B, Serratrice J, Rey J, et al. Chronic hepatitis C virus infection associated with a generalized granuloma annulare. J Am Acad Dermatol 2000; 43:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/50\">",
"      Wu SJ, Nguyen EQ, Nielsen TA, Pellegrini AE. Nodular tertiary syphilis mimicking granuloma annulare. J Am Acad Dermatol 2000; 42:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/51\">",
"      Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992; 72:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/52\">",
"      Rallis E, Stavropoulou E, Korfitis C. Granuloma annulare of childhood successfully treated with potent topical corticosteroids previously unresponsive to tacrolimus ointment 0.1%: report of three cases. Clin Exp Dermatol 2009; 34:e475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/53\">",
"      Sparrow G, Abell E. Granuloma annulare and necrobiosis lipoidica treated by jet injector. Br J Dermatol 1975; 93:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/54\">",
"      Blume-Peytavi U, Zouboulis CC, Jacobi H, et al. Successful outcome of cryosurgery in patients with granuloma annulare. Br J Dermatol 1994; 130:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/55\">",
"      Grundmann-Kollmann M, Ochsendorf FR, Zollner TM, et al. Cream psoralen plus ultraviolet A therapy for granuloma annulare. Br J Dermatol 2001; 144:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/56\">",
"      Salomon N, Walchner M, Messer G, et al. [Bath-PUVA therapy of granuloma annulare]. Hautarzt 1999; 50:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/57\">",
"      Frigerio E, Franchi C, Garutti C, et al. Multiple localized granuloma annulare: ultraviolet A1 phototherapy. Clin Exp Dermatol 2007; 32:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/58\">",
"      Nistic&ograve; SP, Saraceno R, Schipani C, et al. Different applications of monochromatic excimer light in skin diseases. Photomed Laser Surg 2009; 27:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/59\">",
"      Do TT, Bailey EC, Wang F, et al. Targeted broadband ultraviolet B phototherapy improves disorders characterized by increased dermal matrix. Br J Dermatol 2009; 161:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/60\">",
"      Kim YJ, Kang HY, Lee ES, Kim YC. Successful treatment of granuloma annulare with topical 5-aminolaevulinic acid photodynamic therapy. J Dermatol 2006; 33:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/61\">",
"      Weisenseel P, Kuznetsov AV, Molin S, et al. Photodynamic therapy for granuloma annulare: more than a shot in the dark. Dermatology 2008; 217:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/62\">",
"      Kerker BJ, Huang CP, Morison WL. Photochemotherapy of generalized granuloma annulare. Arch Dermatol 1990; 126:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/63\">",
"      Hindson TC, Spiro JG, Cochrane H. PUVA therapy of diffuse granuloma annulare. Clin Exp Dermatol 1988; 13:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/64\">",
"      Dorval JC, Leroy JP, Mass&eacute; R. [Disseminated granuloma annulare following puvatherapy]. Ann Dermatol Venereol 1979; 106:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/65\">",
"      Grieco T, Cantisani C, Faina P, et al. Tacrolimus 0.1% and granuloma annulare: description of three cases. J Eur Acad Dermatol Venereol 2009; 23:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/66\">",
"      Badavanis G, Monastirli A, Pasmatzi E, Tsambaos D. Successful treatment of granuloma annulare with imiquimod cream 5%: a report of four cases. Acta Derm Venereol 2005; 85:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/67\">",
"      Kuwahara RT, Naylor MF, Skinner RB. Treatment of granuloma annulare with topical 5% imiquimod cream. Pediatr Dermatol 2003; 20:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/68\">",
"      Weiss JM, Muchenberger S, Sch&ouml;pf E, Simon JC. Treatment of granuloma annulare by local injections with low-dose recombinant human interferon gamma. J Am Acad Dermatol 1998; 39:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/69\">",
"      Sniezek PJ, DeBloom JR 2nd, Arpey CJ. Treatment of granuloma annulare with the 585 nm pulsed dye laser. Dermatol Surg 2005; 31:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/70\">",
"      Sliger BN, Burk CJ, Alvarez-Connelly E. Treatment of granuloma annulare with the 595 nm pulsed dye laser in a pediatric patient. Pediatr Dermatol 2008; 25:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/71\">",
"      Stephenson S, Nedorost S. Granuloma annulare: dramatically altered appearance after application of 5% imiquimod cream. Pediatr Dermatol 2008; 25:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/72\">",
"      Jain S, Stephens CJ. Successful treatment of disseminated granuloma annulare with topical tacrolimus. Br J Dermatol 2004; 150:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/73\">",
"      Rigopoulos D, Prantsidis A, Christofidou E, et al. Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br J Dermatol 2005; 152:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/74\">",
"      Muchenberger S, Sch&ouml;pf E, Simon JC. Phototherapy with UV-A-I for generalized granuloma annulare. Arch Dermatol 1997; 133:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/75\">",
"      Schnopp C, Tzaneva S, Mempel M, et al. UVA1 phototherapy for disseminated granuloma annulare. Photodermatol Photoimmunol Photomed 2005; 21:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/76\">",
"      Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/77\">",
"      Kroft EB, Berkhof NJ, van de Kerkhof PC, et al. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol 2008; 59:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/78\">",
"      Batchelor R, Clark S. Clearance of generalized papular umbilicated granuloma annulare in a child with bath PUVA therapy. Pediatr Dermatol 2006; 23:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/79\">",
"      Schmutz JL. PUVA therapy of granuloma annulare. Clin Exp Dermatol 2000; 25:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/80\">",
"      Setterfield J, Huilgol SC, Black MM. Generalised granuloma annulare successfully treated with PUVA. Clin Exp Dermatol 1999; 24:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/81\">",
"      Simon M Jr, von den Driesch P. Antimalarials for control of disseminated granuloma annulare in children. J Am Acad Dermatol 1994; 31:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/82\">",
"      Carlin MC, Ratz JL. A case of generalized granuloma annulare responding to hydroxychloroquine. Cleve Clin J Med 1987; 54:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/83\">",
"      Cannistraci C, Lesnoni La Parola I, Falchi M, Picardo M. Treatment of generalized granuloma annulare with hydroxychloroquine. Dermatology 2005; 211:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/84\">",
"      Looney M, Smith KM. Isotretinoin in the treatment of granuloma annulare. Ann Pharmacother 2004; 38:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/85\">",
"      Pasmatzi E, Georgiou S, Monastirli A, Tsambaos D. Temporary remission of disseminated granuloma annulare under oral isotretinoin therapy. Int J Dermatol 2005; 44:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/86\">",
"      Tang WY, Chong LY, Lo KK. Resolution of generalized granuloma annulare with isotretinoin therapy. Int J Dermatol 1996; 35:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/87\">",
"      Schleicher SM, Milstein HJ, Lim SJ, Stanton CD. Resolution of disseminated granuloma annulare with isotretinoin. Int J Dermatol 1992; 31:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/88\">",
"      Baskan EB, Turan A, Tunali S. A case of generalized granuloma annulare with myelodysplastic syndrome: successful treatment with systemic isotretinoin and topical pimecrolimus 1% cream combination. J Eur Acad Dermatol Venereol 2007; 21:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/89\">",
"      Schleicher SM, Milstein HJ. Resolution of disseminated granuloma annulare following isotretinoin therapy. Cutis 1985; 36:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/90\">",
"      Czarnecki DB, Gin D. The response of generalized granuloma annulare to dapsone. Acta Derm Venereol 1986; 66:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/91\">",
"      Steiner A, Pehamberger H, Wolff K. Sulfone treatment of granuloma annulare. J Am Acad Dermatol 1985; 13:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/92\">",
"      Mart&iacute;n-S&aacute;ez E, Fern&aacute;ndez-Guarino M, Carrillo-Gij&oacute;n R, et al. [Efficacy of dapsone in disseminated granuloma annulare: a case report and review of the literature\]. Actas Dermosifiliogr 2008; 99:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/93\">",
"      Filotico R, Vena GA, Coviello C, Angelini G. Cyclosporine in the treatment of generalized granuloma annulare. J Am Acad Dermatol 1994; 30:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/94\">",
"      Ho VC. Cyclosporine in the treatment of generalized granuloma annulare. J Am Acad Dermatol 1995; 32:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/95\">",
"      Fiallo P. Cyclosporin for the treatment of granuloma annulare. Br J Dermatol 1998; 138:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/96\">",
"      Spadino S, Altomare A, Cainelli C, et al. Disseminated granuloma annulare: efficacy of cyclosporine therapy. Int J Immunopathol Pharmacol 2006; 19:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/97\">",
"      Granjo E, Lima M, Lopes JM, et al. Response to cyclosporine in a patient with disseminated granuloma annulare associated with CD4+/CD8+(dim)/CD56+ large granular lymphocytic leukemia. Arch Dermatol 2002; 138:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/98\">",
"      Ma A, Medenica M. Response of generalized granuloma annulare to high-dose niacinamide. Arch Dermatol 1983; 119:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/99\">",
"      Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-&alpha; treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010; 11:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/100\">",
"      Rosmarin D, LaRaia A, Schlauder S, Gottlieb AB. Successful treatment of disseminated granuloma annulare with adalimumab. J Drugs Dermatol 2009; 8:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/101\">",
"      Werchau S, Enk A, Hartmann M. Generalized interstitial granuloma annulare--response to adalimumab. Int J Dermatol 2010; 49:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/102\">",
"      Knoell KA. Efficacy of adalimumab in the treatment of generalized granuloma annulare in monozygotic twins carrying the 8.1 ancestral haplotype. Arch Dermatol 2009; 145:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/103\">",
"      Rubel DM, Wood G, Rosen R, Jopp-McKay A. Generalised granuloma annulare successfully treated with pentoxifylline. Australas J Dermatol 1993; 34:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/104\">",
"      Hall CS, Zone JJ, Hull CM. Treatment of recalcitrant disseminated granuloma annulare with hydroxyurea. J Am Acad Dermatol 2008; 58:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/105\">",
"      Weber HO, Borelli C, R&ouml;cken M, Schaller M. Treatment of disseminated granuloma annulare with low-dose fumaric acid. Acta Derm Venereol 2009; 89:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/106\">",
"      Wollina U. Granuloma annulare disseminatum responding to fumaric acid esters. Dermatol Online J 2008; 14:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/107\">",
"      Duarte AF, Mota A, Pereira MA, et al. Generalized granuloma annulare--response to doxycycline. J Eur Acad Dermatol Venereol 2009; 23:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/108\">",
"      Marcus DV, Mahmoud BH, Hamzavi IH. Granuloma annulare treated with rifampin, ofloxacin, and minocycline combination therapy. Arch Dermatol 2009; 145:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/109\">",
"      Piaserico S, Zattra E, Linder D, Peserico A. Generalized granuloma annulare treated with methylaminolevulinate photodynamic therapy. Dermatology 2009; 218:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/110\">",
"      Karsai S, Hammes S, R&uuml;tten A, Raulin C. Fractional photothermolysis for the treatment of granuloma annulare: a case report. Lasers Surg Med 2008; 40:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/111\">",
"      Sabuncuolu H, Oge K, S&ouml;ylemezolu F, Salam A. Subcutaneous granuloma annulare of the scalp in childhood: a case report and review of the literature. Turk Neurosurg 2007; 17:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/112\">",
"      Jankowski PP, Krishna PH, Rutledge JC, et al. Surgical management and outcome of scalp subcutaneous granuloma annulare in children: case report. Neurosurgery 2008; 63:E1002; discussion E1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/113\">",
"      McNeal S, Daw JL Jr. Subcutaneous granuloma annulare: an unusual presentation in the eyelids and scalp. Ann Plast Surg 2005; 55:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/114\">",
"      Lopez-Navarro N, Castillo R, Gallardo MA, et al. Successful treatment of perforating granuloma annulare with 0.1% tacrolimus ointment. J Dermatolog Treat 2008; 19:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/115\">",
"      Levin NA, Patterson JW, Yao LL, Wilson BB. Resolution of patch-type granuloma annulare lesions after biopsy. J Am Acad Dermatol 2002; 46:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/116\">",
"      Penas PF, Jones-Caballero M, Fraga J, et al. Perforating granuloma annulare. Int J Dermatol 1997; 36:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/24/22922/abstract/117\">",
"      Wells RS, Smith MA. The Natural History of Granuloma Annulare. Br J Dermatol 1963; 75:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13705 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-063D528ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22922=[""].join("\n");
var outline_f22_24_22922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35143281\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143160\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143167\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143174\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143181\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35143190\">",
"      Localized GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35143197\">",
"      Generalized GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35143204\">",
"      Subcutaneous GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35143218\">",
"      Perforating GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19689471\">",
"      Patch GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67047128\">",
"      Other variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19690202\">",
"      ASSOCIATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19690225\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19690232\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H622572\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636707\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143232\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143239\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19689888\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19689903\">",
"      Annular lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67046911\">",
"      Other lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H345299\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35143253\">",
"      Localized GA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20262888\">",
"      - First-line therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20262895\">",
"      Topical or intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20262978\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35143260\">",
"      Generalized GA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H880145\">",
"      - First-line therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H346142\">",
"      Topical or intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H346111\">",
"      Topical calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20263475\">",
"      UVA1 phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20263482\">",
"      Photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H880137\">",
"      - Systemic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346393\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19690484\">",
"      Other GA variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143267\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143274\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35143281\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13705\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13705|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/51/32563\" title=\"picture 1A\">",
"      Granuloma annulare hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/32/19968\" title=\"picture 1B\">",
"      Granuloma annulare foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/4/2115\" title=\"picture 1C\">",
"      Localized granuloma annulare on hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/43/31410\" title=\"picture 1D\">",
"      Granuloma annulare on hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/17/41233\" title=\"picture 2\">",
"      Localized granuloma annulare on hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/33/22032\" title=\"picture 3A\">",
"      Disseminated granuloma annulare - annular lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/43/15026\" title=\"picture 3B\">",
"      Disseminated granuloma annulare - annular lesions on leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/49/24336\" title=\"picture 3C\">",
"      Disseminated granuloma annulare - papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/53/36688\" title=\"picture 3D\">",
"      Disseminated granuloma annulare on trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/36/15936\" title=\"picture 3E\">",
"      Disseminated granuloma annulare - multiple papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/63/34801\" title=\"picture 3F\">",
"      Granuloma annulare on foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/0/28672\" title=\"picture 4\">",
"      Subcutaneous granuloma annulare - finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/23/37232\" title=\"picture 5\">",
"      Patch granuloma annulare",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/14/42208\" title=\"picture 6\">",
"      Linear granuloma annulare",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/43/37560\" title=\"picture 7\">",
"      Pathology of granuloma annulare - early lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/9/29847\" title=\"picture 8A\">",
"      Pathology of granuloma annulare - palisading granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/21/44374\" title=\"picture 8B\">",
"      Pathology of granuloma annulare - palisading granuloma periphery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/12/3271\" title=\"picture 8C\">",
"      Pathology of granuloma annulare - necrobiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/8/44167\" title=\"picture 9\">",
"      Pathology of granuloma annulare - perforating",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/24/3459\" title=\"picture 10\">",
"      Tinea corporis on leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/48/13059\" title=\"picture 11\">",
"      Annular lichen planus - penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/38/8803\" title=\"picture 12\">",
"      Cutaneous sarcoidosis - annular plaques on neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/36/13889\" title=\"picture 13A\">",
"      Annular elastolytic giant cell granuloma - arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/60/962\" title=\"picture 13B\">",
"      Annular elastolytic giant cell granuloma - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/63/18417\" title=\"picture 14A\">",
"      Erythema annulare centrifugum - light skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/23/28016\" title=\"picture 14B\">",
"      Erythema annulare centrifugum - dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/11/28862\" title=\"picture 15\">",
"      Interstitial granulomatous dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/22/12642\" title=\"picture 16\">",
"      Papular secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/38/32353\" title=\"picture 17\">",
"      Eruptive xanthomata forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/26/20897\" title=\"picture 18A\">",
"      Eruptive syringoma - neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/52/36673\" title=\"picture 18B\">",
"      Eruptive syringoma - shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/4/28737\" title=\"picture 19\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/25/22930\" title=\"picture 20A\">",
"      Perforating folliculitis - hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/37/1619\" title=\"picture 20B\">",
"      Perforating folliculitis - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/63/23551\" title=\"picture 21\">",
"      Elastosis perforans serpiginosa - arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/9/13461\" title=\"picture 22\">",
"      Molluscum on face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/12/32963\" title=\"picture 23\">",
"      Parapsoriasis large plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13705|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35688?source=related_link\">",
"      Approach to the patient with annular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43001?source=related_link\">",
"      Comorbid disease in psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=related_link\">",
"      Cutaneous manifestations of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=related_link\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/23/35185?source=related_link\">",
"      Patient information: Granuloma annulare (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_24_22923="Spitz nevus variants";
var content_f22_24_22923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spitz nevus/tumor and variants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Spitz nevus: junctional, compound, dermal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desmoplastic Spitz tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pigmented spindle cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plexiform pigmented spindle (and epithelioid) cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spitz tumor, halo variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent Spitz tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Spitz tumor with atypical features (atypical Spitz tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pagetoid Spitz tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Spitz&nbsp;tumor with architectural disorder and cytologic atypia (dysplastic Spitz tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spitz&nbsp;tumor with atypical features and indeterminate biologic potential",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Spitzoid\", Spitz-like melanoma, malignant Spitz tumor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Barnhill RL, Cerroni L, Cook M, et al. State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: Outcome of an international workshop. Adv Anat Pathol 2010; 17:73. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22923=[""].join("\n");
var outline_f22_24_22923=null;
var title_f22_24_22924="Numeric portraits homeless";
var content_f22_24_22924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Numeric portrait of homelessness in 23 US cities, 2005*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Data in percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Ethnicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Black",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hispanic",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Native American",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asian",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         100",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Category",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Single men",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Single women",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unaccompanied children",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Families with children&bull;",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         100",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Homeless families",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent of families with single-parent",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent of children under age 5",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent of shelter requests unmet",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This data is from urban homeless shelters. It does not address persons either \"doubled-up\" or \"sleeping rough\" (see text), two large subsets harder to survey.",
"     <br>",
"      &bull; It is widely reported, but less-well innumerated, that the proportion of homeless people who are in family units is \"much greater\" in rural settings.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hunger and Homelessness Survey, US Conference of Mayors. Available at file://usmayors.org/uscm/hungersurvey/2006/report06.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22924=[""].join("\n");
var outline_f22_24_22924=null;
var title_f22_24_22925="Precaution requirements after treatments with 131-I carcinoma";
var content_f22_24_22925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of precaution requirements after treatments with 131-I: Thyroid carcinoma/remnant ablation*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        mCi (MBq) administered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        50",
"        <br/>",
"        (1850)",
"       </td>",
"       <td class=\"subtitle2\">",
"        100",
"        <br/>",
"        (3700)",
"       </td>",
"       <td class=\"subtitle2\">",
"        150",
"        <br/>",
"        (5550)",
"       </td>",
"       <td class=\"subtitle2\">",
"        200",
"        <br/>",
"        (7400)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Restricted periods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        <em>",
"         Nighttime restrictions",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sleep in a separate (6-feet separation) bed from adults for days",
"        <sup>",
"         &bull;",
"        </sup>",
"        shown.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sleep in a separate bed from pregnant partners, infant, or child for days shown.",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        <em>",
"         Daytime restrictions",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        You may return to work after days shown.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Maximize your distance (6 feet) from children and pregnant women for days shown.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Avoid extended time in public places for days shown.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Duration of safe travel by public transportation (bus, air, etc)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        <em>",
"         Travel time (hours) without exceeding regulatory dose limit",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day",
"        <sup>",
"         &bull;",
"        </sup>",
"        0 (beginning with treatment)",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 1",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 2",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 3",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Examples should be modified to meet local and specific patient needs. These examples are based on dose rate of 0.17 mrem h",
"    <sup>",
"     -1",
"    </sup>",
"    mCi",
"    <sup>",
"     -1",
"    </sup>",
"    at 1 m, 500 mrem per year for family member and caregiver, 100 mrem for pregnant women, children, and the public, and occupancy factors for adults of 0.25 except for sleeping 0.33. Resumption of sleeping with a partner assumes a distance of 0.3 m.",
"    <div class=\"footnotes\">",
"     * Assumes that disappearance of",
"     <sup>",
"      131",
"     </sup>",
"     I is biexponential with early effective T",
"     <sub>",
"      1/2",
"     </sub>",
"     of about 0.76 days, and 2 percent uptake in remnant with effective T",
"     <sub>",
"      1/2",
"     </sub>",
"     of about 7.3 days. Consider formal dosimetry for larger administered doses given to patients with functioning carcinoma.",
"     <sup>",
"      131",
"     </sup>",
"     I kinetics in euthyroid patients stimulated by recombinant human thyrotropin may differ from those used here.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Day = 24-hour cycle.",
"      <br>",
"       &Delta; Assumes 100 mrem limit and 0.3 m distance.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The American Thyroid Association Taskforce on Radioiodine Safety. Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine 131-I: Practice Recommendations of the American Thyroid Association. Thyroid 2011; 21:335. Copyright &copy; 2011 Mary Ann Liebert Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22925=[""].join("\n");
var outline_f22_24_22925=null;
var title_f22_24_22926="Peptide hormone synthesis";
var content_f22_24_22926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Peptide hormone synthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peptide hormone synthesis begins with transcription of genomic DNA into messenger RNA (mRNA) which is then translated into protein. Preprohormone in ribosomes is modified by post-translational processing in the Golgi apparatus into various peptide cleavage products that are eventually secreted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22926=[""].join("\n");
var outline_f22_24_22926=null;
var title_f22_24_22927="Gastric xanthoma CPC Endosc";
var content_f22_24_22927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric xanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing two small 4 mm yellow nodules in the gastric fundus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas Horst, MD and Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_24_22927=[""].join("\n");
var outline_f22_24_22927=null;
